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Abstract 
 
The auxin indole-3-acetic acid (IAA) plays a central role in plant growth and development 
and many plant-associated microbes produce IAA. Several IAA biosynthetic pathways 
have been identified in microbes which use the precursor tryptophan. Pantoea sp. YR343, 
which was isolated from the Populus deltoides rhizosphere, is a robust plant root colonizer 
that produces IAA. Using genomic and metabolomics analyses, we predicted that the 
indole-3-pyruvate (IPA) pathway is the major pathway in Pantoea sp. YR343 for IAA 
production. To better understand IAA biosynthesis and the effects of IAA exposure on cell 
physiology, we performed proteomics on Pantoea sp. YR343 grown in the presence of 
tryptophan or IAA. These data indicate that indole-3-pyruvate decarboxylase, a major 
enzyme in the IPA pathway, is upregulated in the presence of both tryptophan and IAA. 
Moreover, exposure to IAA induced changes in the proteome, including upregulation of 
proteins predicted to function in carbohydrate and amino acid transport and EPS 
biosynthesis. Finally, we constructed a mutant in which the ipdC gene was disrupted. The 
ΔipdC mutant showed a significant decrease in IAA production, but was still able to 
efficiently colonize poplar, suggesting that microbial IAA production is not required for 
initiation of plant association. 
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Chapter 1  
Introduction 
 
In community ecology, it is the assemblage of multiple species that creates the 
fundamental traits found in complex biosystems. This assemblage, though, is also at the 
center of the profound consequences these communities have on larger ecological 
environments [1-3]. In these environments, plants compete for nutrients and space, and 
this directly affects the microbial and fungal communities which surround the plant’s root 
system. Plants, microbes, and fungi exchange nutrients as a collective in order to 
maintain a balanced ecological environment that is beneficial for the entire community [4]. 
Interaction networks within these communities are complex, and include plant-plant, 
plant-fungal, plant-microbe, fungal-fungal, fungal-microbe, and microbe-microbe 
interactions [5-10]. How this community is structured and how its members communicate 
with each other, however, is poorly understood.  
Multicellular organisms such as plants and fungi are comprised of complex biological 
systems, including a variety of microbes, which is referred to as their microbiome. A key 
area of research is in the understanding of how this microbiome contributes to the 
phenotypes and responses of the plant to environmental stimuli [11-15]. All microbiome 
communities, whether they are found on the coasts, in woodlands, or deserts, develop 
intimate associations with plants coexisting within the same landscape [16-19]. These 
communities influence each other both directly and indirectly. Furthermore, these 
communities all form relationships that can be symbiotic, mutual, commensal, or 
harmful/parasitic [20-22]. Studying the biocomplexity within and between a 
multiorganismal system allows us to better predict environmental responses to climate 
challenges over time, benefiting both agriculture and bio-energy production [23, 24]. 
Biocomplexity is the study of multi-component biological systems and their environmental 
responses to various chemical and biological signals [25]. As individual organisms, plants, 
microbes, and fungi each have their own biochemical processes that are influenced by 
their internal interconnectivity and metabolic processes. These organisms, however, 
influence each other within their environment by transferring genetic components and 
biomolecules between one another. Doing so ultimately helps these organisms to 
construct their collective ecosystem. Although this idea is increasingly recognized, there 
is still poor understanding of the complexities found between these reactive systems and 
how they influence each other [2, 26]. Understanding plant microbial communities is 
extremely difficult task because it involves isolating new organisms and characterizing 
them quickly. The challenge to understanding these complex systems first happens 
individually in specific organisms. These attributes are then studied on a community level. 
To achieve this, plant communities are first isolated from their environment. Then the 
community is teased apart by isolating the various plant, fungi and bacteria components. 
Next, the organisms are characterized on an individual level. Finally, the environment is 
reconstructed and studied at the community level. 
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Understanding these complex functional processes within a community requires a variety 
of integrated technologies to reveal an organism’s precise internal molecular processes. 
To understand complex biological systems, it is important to understand what is 
happening globally within the entire community, as well as on an individual level. The field 
of omics is utilized to study complex biological systems and to capture all processes within 
the central dogma. Omics is a field of study in biology used to gather information from 
DNA, RNA, proteins, and metabolites to better understand the functionality of complex 
biological systems found under certain conditions [27]. Additionally, omics is also utilized 
as an analytical tool used to assist in the discovery of unknowns. Omics can be broken 
down into a variety of fields to capture specific and individual biological processes. This 
data can then be comparatively analyzed in order to piece relevant biological information 
back together into a cohesive whole, Figure 1.1.  
 
 
 
Figure 1.1: “Omics Cascade.” Multiple omics approaches can be used collectively or 
individually to identify and define a specific phenotype or function of an organism [28].  
 
 
In a biological system, the comparison of genes via genomics allows for the study of an 
organism at the genomic level. Genomic resources of these plant-microbe studies are 
important for researchers. These resources enable researchers to better predict genetic 
variations, identify gene homologs, predict structural/functional roles, and map genes to 
specific regions. Based on these genomic predictions, researchers can then go back and 
perform experiments to validate potential biosynthetic pathways associated with 
candidate genes [29]. Although genomics is a useful tool used for initial characterization, 
it is not without its drawbacks. Genomics can only give you predicted functions based on 
prior genome knowledge. Limitations often include annotation errors, sequence alignment 
errors, and unknown predictions [30]. 
Transcriptomics, a field tightly associated with genomics, allows for the investigation of 
RNA.  This field of omics is important because it allows for the detection of specific gene 
expression networks in complex organisms. Popular approaches to studying RNA 
transcripts within a biological system include RNA sequencing (RNA-seq), quantitative 
reverse transcription polymerase chain reaction (qRT-PCR), and reverse transcription 
polymerase chain reaction (RT-PCR) [31]. The advantages of qRT-PCR vs RT-PCR 
include: higher resolution, increased signal based on a fluorescent tag, and direct 
quantification. qRT-PCR and RT-PCR, while effective, are limited to amplifying known 
genomic regions of the DNA. On the other hand, RNA-seq is also a powerful technology 
with many advantages such as an easy work flow, detection of unknown transcripts in 
samples and provides a quick turnaround, it has, as with any technology, drawbacks. 
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Some of these drawbacks include large data output, low storage capabilities and 
normalization [31].   
Alternatively, Proteomics helps identify proteins. This field can be used to determine 
protein-protein interactions, examine post-translational modification, identify protein 
complexes, and identify proteins in, for example, unknown  plant or dirt samples [32]. 
Although proteomics is a powerful approach to identifying functional aspects of 
organisms, one major disadvantage is that this technique typically only detects 50% of 
the proteins being expressed at a given time in unicellular organisms and may only detect 
10% in higher Eukaryotes, leaving a very narrow window for interpretation [33]. 
Additionally, proteomic extraction efficiencies may be low and instrument sensitivities may 
present a problem when detecting reasonable peptides. 
Finally, Metabolomics identifies either known or unknown secondary metabolites involved 
in complex chemical processes. The results of this type of study are often quantified by 
Gas Chromatography-Mass Spectrometry (GC-MS) [34, 35]. In addition to obtaining 
functional information, integrative omics can determine information about cellular 
localization, biological networks, post-translational modifications, and much more [36, 
37]. Limitations in metabolomics include the scope of the experiment, measurement 
accuracy, sample preparation/derivatization, extraction methods, and available 
metabolite database  [38, 39].  
Combining these powerful approaches, often referred to as integrative omics, provides 
detailed information about a biological system in real time. This approach also allows for 
the collection of functional information about a complex biological organism. That 
information is then ultimately used to study a community as a cohesive whole. Integrative 
omics is a powerful approach to studying systems biology. However, it is not without its 
shortcomings. One of the most apparent drawbacks is that bioinformatic pipelines are 
limited. Furthermore, data storage is problematic, and only one, single dimensional, 
analysis of a specific time point is available per experiment [27]. Even with its drawbacks, 
though, integrative omic approaches provide a powerful and effective means for 
understanding how communities influence each other and integrate together.  It is 
necessary to use a combination of all of these analyses in order to assert significant 
biological predictions [40].  
The overall scope of this dissertation is to understand what influences the microbiome of 
P. deltoides. P. deltoides is a host to an abundant and diverse microbiome, which can 
influence its growth and productivity. The mechanisms by which plants and microbes 
influence each other are only starting to be understood. Understanding how beneficial 
interactions between microbes and plant host are initiated and maintained will inform 
strategies for improving plant growth and productivity. These efforts will help us determine 
how these interactions ultimately influence the plant host relationship within Populus 
deltoides, which will help inform strategies to develop more efficient renewable energy 
resources. 
Populus deltoides (poplar) is a model organism used for bioenergy production and 
agricultural studies. This species was selected for the following reasons: its genome has 
been sequenced, it’s a keystone species, it has broad geographic distribution, fast growth, 
abundance, and finally, numerous tools have been generated for manipulating its genetic 
code [41, 42]. Also, P. deltodies and its root-associated environment consist of an 
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integrated infrastructure which contributes to the overall health of the plant [43]. In order 
to understand how environmental factors influence P. deltodies, the rhizosphere and 
endosphere must be studied. Examination of these microbiomes is important because 
they are currently thought to contribute to the overall health and viability of P. deltodies 
[5, 44, 45]. The thin layer surrounding the roots of P. deltoides is known as the 
rhizosphere. This area contains rhizobacteria which can influence the plant either 
indirectly or directly. Some of the bacteria associated with P. deltoides are beneficial and 
can influence the growth and health of the host by acting as bioprotectants, biofertilizers, 
and/or biostimulants [46, 47].  
The beneficial rhizobacteria mentioned previously are known as plant growth promoting 
rhizobacteria (PGPR) [48-50]. PGPR are bacteria which not only promote plant growth, 
but also aggressively colonize roots to from symbiotic relationships with its plant host [47, 
51]. Root colonization of PGPR is a crucial characteristic of bacteria for the purposes of 
this study as it allows the bacteria to mediate resource acquisition within the rhizosphere 
[52, 53]. This mediation allows the bacteria to control various biochemical processes 
associated within the rhizosphere and helps to maintain a beneficial relationship [53]. 
Controlled resource acquisition within the rhizosphere directly influences the overall plant 
viability. Bacteria do this by controlling hormone levels, preventing pathogenicity, and 
maintaining nitrogen, phosphorus or iron levels as well. Additionally, it helps provide key 
metabolites, such as indole-3-acetic acid (IAA), which have been shown to improve plant 
growth and development [54, 55].  
The microbiome of P. deltodies and P. trichocarpa have been the subject of recent 
studies. In 2009, as a collaborative effort, our research group isolated over 3000 bacterial 
species from the native P. deltoides and P. trichocarpa rhizospheres [42]. The specimens 
were collected across a variety of field sites including the Caney Fork River site and Edgar 
Evans State park, both located in the state of Tennessee, Yadkin River, North Carolina 
and sites in Oregon [42, 56]. Following soil extraction, tertiary fine roots were removed. 
Then, individual bacteria were isolated, sequenced and characterized. One class of the 
bacteria isolated from the P. deltoides rhizosphere is known as Pantoea. The Pantoea 
genus is a gram-negative bacteria and consists of approximately 20 different species [57]. 
Pantoea may aid in bioremediation and can act as a biocontrol for plants [58-60]. These 
factors qualify this species of isolates as a unique niche for experimental development. 
Various Pantoea strains have been isolated from sources including environmental water, 
soil, insects, animals and humans. Each Pantoea strain has the potential to be either 
pathogenic or non-pathogenic, depending on its host environment [61, 62]. 
Interestingly, many species within the genus Pantoea have been found associated with 
plants [57].   However, some of these species, such as P. stewartii and P. rodasii, are 
known pathogens of corn and eucalyptus respectively [63, 64]. Still, other strains have 
been shown to have beneficial effects on a plant host.  For example, P. agglomerans is 
thought to promote plant growth by enhancing root growth, which can increase water and 
mineral uptake [65].  Indeed, this promotion of growth is thought to be the result of IAA 
production. IAA produced by bacteria can influence plant hosts in diverse ways. Such 
influences include induction of tissue differentiation, cell division, elongation, lateral-root 
formation, and cambial growth, Figure 1.2 [66, 67]. Genomic analyses of P. agglomerans 
also indicated the presence of a gene encoding indole-3-pyvuvate decarboxylase (IpdC).  
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Figure 1.2: Bacteria that produce IAA influence its plant host in a variety of ways including: 
root initiation, it helps loosen plant cell walls to release exudates, stimulates root hair 
overproduction, increases lateral root formation, bacterial IAA can act as a signaling 
molecule to both the plant and bacteria, it aids in root elongation, and bacterial 
colonization.  
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Figure 1.3: Plant growth promoting characteristics of Pantoea sp. YR343. A) Pantoea sp. 
YR343 is genetically tractable, confocal image of Pantoea sp. YR343 expressing GFP. 
B) Pantoea sp. YR343 forms biofilms in both minimal and rich media. C) Pantoea sp. 
YR343 colonizing the roots of Arabidopsis thaliana and initiating lateral root formation. D) 
Pantoea sp. YR343 has swimming and swarming motility. E) Salkowskis test for indole 
production in Pantoea sp. YR343. F) Pantoea sp. YR343 produces about 4µg/mL of 
indoles. 
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This is one of the main genes associated with IAA biosynthesis through the indole-
pyruvate (IPA) pathway [65]. Equally important, a metabolite analysis of P. dispersa 
confirmed  that it also produces IAA through the IPA pathway [68].  
Panotea sp. YR343, one of our isolates from P. deltoides, is a gram-negative γ-
proteobacterium [43]. According to our initial analysis, Panotea sp. YR343 is capable of 
solubilizing phosphate, forming biofilms, and colonizing roots. Furthermore, it is 
genetically tractable, can initiates lateral root formation in the presence of a plant host, 
and secretes the phytohormone IAA. As such, Panotea sp. YR343 exhibits key 
characteristics of a plant growth promoting bacteria, Figure 1.3 [69]. Pantoea sp. YR343 
can also colonize other plants, including Triticum aestivum and Arabidopsis thaliana. In 
fact, the colonization of these plants by Pantoea sp. YR343 resulted in increased lateral 
root production [70]. Similar to P. agglomerans and P. dispersa, genomic analyses 
indicated the presence of an ipdC homolog (PMI39_00059), suggesting the possibility 
that Pantoea sp. YR343 may synthesize IAA through the IPA pathway.  
Multiple IAA biosynthetic pathways have been described in microbes, most of which 
require the precursor tryptophan [71-73]. The associated tryptophan-dependent 
pathways are as follows:  indole-3-acetonitrile (IAN), indole-3-acetamide (IAM), 
tryptophan side-chain oxidase (TSO), indole-3-pyruvate (IPA), and finally, the tryptamine 
pathway, Figure 1.4 [71, 74].  IAA production has also been studied in many different 
microbes. These microbes include Azospirillum brasilense, Enterobacter cloacae UW5, 
Pantoea dispersa, Pantoea agglomerans, and Pseudomonas putida [65, 67, 68, 75, 76]. 
Evidence of this process at work can be found in the A. brasilense microbe, a plant growth 
promoting bacteria that synthesizes IAA primarily through the indole-3-pyruvate pathway 
[77].  In A. brasilense, a deletion of the ipdC gene which encodes indole-3-pyruvate 
decarboxylase resulted in a drastic reduction in IAA production in the mutant. In fact, IAA 
production in the mutant was 90 percent below wild type levels [78]. The ipdC mutant 
strain was still capable of IAA production, however. This suggested the presence of a 
second biosynthetic pathway [79]. Moreover, the presence of IAA itself induced ipdC gene 
expression in A. brasilense, further suggesting that IAA biosynthesis is a highly regulated 
process [76, 80, 81].   
To test the prediction that Pantoea sp. YR343 produces IAA through the IPA pathway, 
and to determine how Pantoea sp. YR343 responds to the presence of tryptophan and 
IAA, we performed proteomic analyses of Pantoea sp. YR343 growing in minimal media, 
supplemented with tryptophan or IAA. In the presence of exogenous tryptophan or IAA, 
we found that the ipdC gene is upregulated in Pantoea sp. YR343. This finding suggests 
that the IPA pathway is active under these conditions. Exposure to IAA also induced other 
changes in the proteome. These changes include the upregulation of proteins which were 
predicted to function in nutrient and mineral uptake, as well as in EPS biosynthesis. 
Finally, we constructed a mutant strain in which the ipdC gene was disrupted.  This mutant 
strain showed a significant decrease in IAA production, but did not show defects in its 
ability to colonize poplar. This suggests that microbial IAA production is not required by 
Pantoea sp. YR343 before initiating plant-microbe interactions.  
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Figure 1.4: Tryptophan biosynthetic pathways in Pantoea sp. YR343, red indicates no 
enzymes found and green indicates enzymes found. Tryptophan side-chain oxidase 
(TSO) pathway, indole-3-pyruvate (IPA) pathway, tryptamine (TA) pathway, Indole-3-
acetonitrile (IAN) pathway, and the indole-3-acetamide (IAM) pathway. 
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Chapter 2 
Methods 
 
2.1 Growth of Pantoea sp. YR343  
Pantoea sp. YR343 was grown in either R2A (R2A Broth Premix, TEKnova, Inc.) or M9 
minimal media (per 1 L, 6 g. NaCl, 1 g NH4Cl, 10 mL filter sterilized 100 mM MgSO4, 20% 
glucose, and 10 mM CaCL2) with shaking at 28°C. For proteomic analyses, Pantoea sp. 
YR343 was grown in M9 medium supplemented with 1mM L-tryptophan or with 5µM, 
50µM or 500µM IAA (Sigma Aldrich).  
2.2 Metabolic analyses 
Pantoea sp. YR343 wild type and ΔipdC cultures were grown in M9 medium with or 
without L-tryptophan (1 mM) to an OD600 of 1.  After centrifugation, the supernatant was 
collected (800 µL) and prepared for metabolite analysis. For acidic and neutral 
metabolites, the supernatants were acidified to pH 2 with hydrochloric acid and then 
extracted with ethyl acetate (800 µL). For basic metabolites (specifically, tryptamine), 
samples were basified to pH 11 with sodium hydroxide and extracted with toluene (800 
µL). Samples were vortexed vigorously and briefly centrifuged, after which a 600-µL 
portion of the organic (top) layer was collected and transferred to a 2-mL glass vial. Next, 
the solvent was evaporated under a stream of argon gas, and the residue was 
resuspended in 100 µL of derivatization agent (BSTFA + TMSCl 99:1). These samples 
were then incubated at 80 °C for 4 h. After derivatization, the sample was diluted with 
900 µL of hexane in the same vial. 
GC/MS analysis was performed with an Agilent 7890A gas chromatograph equipped with 
a 7693A automatic liquid sampler, an HP-5ms capillary column (30 m long × 0.25 mm 
inside diameter with a 0.25-µm capillary film of 5% phenyl methylsilicone) and a 5975C 
mass-sensitive detector. Splitless injections of 1 µL were made at an inlet temperature of 
270 °C with a 15-s dwell time (needle left in the inlet after injection), an initial column 
temperature of 60 °C and helium carrier gas at a constant flow of 1 mL/min. After 2 min 
at 60 °C, the temperature was ramped at 20 °C/min to 200 °C, then at 10 °C/min to 270 °C 
and finally 30 °C/min to 300 °C, with a 2-min hold at 300 °C. The detector was operated 
with a transfer line temperature of 300 °C, source temperature of 230 °C and quadrupole 
temperature of 150 °C. After a 5-min solvent delay, electron-impact mass spectra from 
50–500 atomic mass units were collected continuously (~3/s) for the duration of the run. 
2.3 Promoter-Reporter (GFP) Construct 
The ipdC (PMI39_00059) promoter region was defined as 350 base pairs upstream from 
the transcription start site and amplified from genomic DNA using the primers 
ipdCprom_(HindIII)For: 5’-CCCAAGCTTGGCTGTTATCGACGCGCG-3’ and 
ipdCprom_(EcoRI) Rev: 5’-CCGGAATTCGCCAACGTTGGGGGTTTT-3’. The fragment 
was subcloned into pPROBE-NT’ [82] and the resulting plasmid was transformed into 
Pantoea sp. YR343 via electroporation and selected on R2A plates containing 50µg 
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kanamycin mL-1 [70]. GFP expression from cells harboring pPROBE-ipdC was monitored 
using a Zeiss LSM710 confocal laser scanning microscope. ImageJ was used for image 
processing [83]. 
2.4 Sample preparation for proteomics 
All chemicals were obtained from Sigma Chemical Co. (St. Louis, MO), unless specified 
otherwise. High performance liquid chromatography- (HPLC-) grade water and other 
solvents were obtained from Burdick & Jackson (Muskegon, MI), 99% formic acid was 
purchased from EM Science (Darmstadt, Germany) and sequencing-grade trypsin was 
acquired from Promega (Madison, WI).   
Frozen cell pellets were ground to a powder under liquid nitrogen and suspended in a 
detergent-based cell lysis buffer (5% SDS, 50 mM Tris-HCl, 0.15M NaCl, 0.1 mM EDTA, 
1 mM MgCl2, pH 8.5).[84] Cells were lysed via 20 min of heat lysis[84] and transferred to 
fresh eppendorf tubes. Trichloroacetic acid was added to samples at a final concentration 
of 25%, and proteins were precipitated by storage at -20 oC overnight. The mixtures were 
thawed briefly and centrifuged at 21,000 g x 20 min. The resulting cell pellets were 
washed with chilled acetone and centrifuged at 21,000 g x 10 min. The acetone wash 
was repeated thrice, discarding supernatants.  The cell pellets were air dried, dissolved 
in guanidine buffer [6M guanidine HCl in Tris-CaCl2 buffer, pH 8.5 (50mM Tris, 10mM 
CaCl2)] and incubated at 60oC for four hours. The total amount of extracted protein was 
measured using the RC/DC protein estimation kit (Bio-Rad Laboratories, Hercules, CA, 
USA) per the manufacturer’s instructions. Bovine serum albumin supplied with the kit was 
used as standard for the assay. The samples were diluted six-fold using Tris-CaCl2 buffer.  
Proteolysis was carried out by adding modified sequencing grade trypsin (Promega, 
Madison, WI) at 40 µg/mg protein with overnight incubation at 37 ℃ and gentle mixing.[85] 
Digested peptides were stored at -80oC until MS analysis. Approximately 75 µg peptides 
per sample was loaded on an in-house packed biphasic column [strong cation exchange, 
SCX (Luna, Phenomenex, Torrance, CA) and reverse-phase C18 (Aqua, Phenomenex, 
Torrance, CA)] as described earlier [85, 86] and subjected to offline desalting.[87]  
2.5 Mass spectrometry 
Peptides were analyzed using a two-dimensional liquid chromatography-tandem mass 
spectrometry approach (2D-LC-MS-MS)[88], implemented as described previously[89].  
Peptides were eluted from the SCX trapping column by eleven successive step gradients 
of increasing ammonium acetate concentration, from 50 mM to 500 mM.  Each SCX step 
gradient eluted a set of peptides onto a 15 cm long reverse-phase (C18) column, where 
they were separated by a two-hour gradient from 100% solvent A (5% CH3CN, 0.1% 
formic acid in water) to 50:50 solvent A:solvent B (70% CH3CN, 0.1% formic acid in 
water).  Peptides eluting from the RP column were introduced via a nanoelectrospray 
source (Proxeon, Odense, Denmark) into a linear ion trap mass spectrometer (LTQ-XL, 
Thermo Scientific, San Jose CA), where data were acquired in data-dependent mode.  
Following each full-scan mass spectrum, up to 5 tandem mass spectra (MS-MS) were 
acquired from the most intense ions in the full-scan spectrum.  For collision-induced 
dissociation, precursor isolation width was 3.0 m/z units, and normalized collision energy 
was 35%.  Dynamic exclusion was employed with a repeat count of 1, exclusion list size 
of 300, repeat duration of 60 sec, and exclusion duration of 180 sec. 
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2.6 Proteomics data analysis 
Peptide identifications were obtained from MS-MS spectra using Myrimatch (version 
2.1.138).[90]  Myrimatch settings included precursor m/z tolerance of 1.5, fragment m/z 
tolerance of 0.5, charge states up to +4, TIC cutoff of 98%, cleavage rule “Trypsin/P”, fully 
tryptic peptides only, with a maximum of two missed cleavage sites per peptide.  The 
protein database for the Myrimatch searches was based on the predicted proteome for 
Pantoea sp. YR343[91], downloaded as 27136.faa from the Department of Energy Joint 
Genome Institute Integrated Microbial Genomes web site [92] on Aug 25, 2014.  
Sequences for common contaminant proteins were appended to the Pantoea sp. YR343 
protein fasta file.  The assembled protein fasta file contained sequences for a total of 4945 
proteins.  Myrimatch employed a decoy database containing sequence-reversed version 
of these proteins to provide an estimate of peptide false discovery rate. 
Protein identifications were assembled from peptide identifications using IDPicker 
(version 3.1.599). [93]  A protein identification required identification of at least two distinct 
peptides.  The maximum false discovery rate for peptide-spectrum matches was set to 
2%. Observed peptide and protein false discovery rates were xx and yy, respectively. 
Analysis of identified proteins for shared peptides was performed using Microsoft Access 
and custom scripts in R.  Proteins sharing all identified peptides were combined into 
protein groups.  Protein abundance was estimated using spectrum count (number of 
tandem mass spectra assigned to that protein [94]), adjusted for shared peptides.[95] 
Normalized spectral abundance factor (NSAF) values [96] were calculated for each 
protein from adjusted spectrum count, with adjusted spectrum count values of 0 replaced 
by 0.3.  Abundance ratios for proteins for which all adjusted spectrum count values were 
zero across the 3 biological replicates of one treatment are therefore inaccurate, and were 
tracked through further analysis steps as “present/absent” proteins (i.e., detected in one 
treatment and not in the other).  Proteins for which an average of < 2.5 tandem mass 
spectra were identified over the 3 biological replicates of a given treatment were identified 
as “low abundance” for that treatment;[97]  the fraction of NSAF represented by low 
abundance proteins ranged from 3-7%. Significant changes in protein abundance for a 
given treatment-control pair were identified using t tests (2-tailed, unpaired, equal 
variances) on log10 transformed NSAF values, with Benjamini-Hochberg correction for 
multiple hypothesis testing. [98] 
2.7 Reverse transcription polymerase chain reaction (RT-PCR)  
Total RNA was extracted from Pantoea sp. YR343 cultures grown in M9 minimal media 
with or without tryptophan using the RNeasy Mini kit (Qiagen) as per manufacturer’s 
instructions. Following RNA elution, 2.5 units RNase-free DNaseI (1 U/µl) (NEB) was 
added to the RNA and incubated at 37˚C for 30 minutes followed by heat inactivation at 
75˚C for 5 minutes.  cDNA was transcribed from 500 ng RNA using ThermoScript RT-
PCR system (Invitrogen) as per manufacturer’s instructions. 5 units of RNaseH was 
added to each sample and incubated for 20 minutes at 37˚C to eliminate residual RNA in 
the cDNA sample. After RNaseH treatment, RT-PCR was performed using FailSafe PCR 
PreMix Selection Kit (Epicentre) and specific primers for ipdC (PMI39_00059) (RT_ipdC 
For: 5’-ATCCCGAAATTGCCTGGGTTG-3’ and RT_ipdCRev: 5’-
GCGGTTAAGGTGTCGGTAAAC-3’) and 16S (RT_16s For: 5’-
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ACGATCCCTAGCTGGTCT-3’ and RT_16s Rev: 5’CTAATCCTGTTTGCTCCC-3’) as a 
control. Gel images were analyzed with ImageJ.  
2.8 Construction of ipdC Mutant 
To generate a disruption mutant for ipdC (PMI39_00059), we first constructed pKnock-
ipdC by ligating the pKnock-Tc vector with a 600 base pair ipdC fragment amplified from 
genomic DNA using ipdC_pknock for (XbaI): 5’-
GCTCTAGAACTCCATCAGCAGGTTGCCGCA-3’ and ipdC-pknock rev (KpnI): 5'- CGG 
GGT ACCCCAAAGGCCGCAGTGCCTTGA-3’ [99]. The resulting plasmid was verified by 
restriction digests and transformed into Pantoea sp. YR343 by electroporation and 
selected on R2A plates containing 5 µg tetracycline ml-1. Disruption of the ipdC gene was 
confirmed by PCR and sequencing.  
2.9 Poplar colonization assays 
Colonization of Populus trichocarpa BESC819 was performed as described previously 
[70].  Briefly, Pantoea YR343-GFP or the ΔipdC mutant were grown overnight in R2A 
media and then the OD600 of each culture was adjusted to 0.01 using fresh R2A.  Five 
plants were inoculated for each treatment. For each plant, sterile clay soil with 1X 
Hoagland’s media was inoculated with 10 ml of either sterile R2A media (control), wild 
type Pantoea YR343-GFP, or the ΔipdC mutant by first mixing the bacterial culture with 
the clay soil, then planting a rooted P. trichocarpa shoot tip.  Plants were incubated in the 
growth chamber for three weeks.  Plant roots were harvested and weighed, then washed 
with 3 ml PBS and a small amount of glass beads to disrupt bacterial attachment.  Colony-
forming units (CFU) were counted for wild type Pantoea YR343-GFP on R2A agar plates 
containing 10 µg ml-1 gentamycin.  CFUs for the ΔipdC mutant were counted on R2A agar 
plates containing 5 µg ml-1 tetracycline.  Control plants showed no background 
contamination when plated on R2A plates with either gentamycin or tetracycline. 
2.10 Biofilm formation assay 
Biofilm formation was quantified using a modified protocol from O’Toole and Kolter, 1998 
[100]. An overnight culture of Pantoea sp. YR343 (WT and ΔipdC) was diluted 1:100 into 
M9 minimal media supplemented with 0.4% w/v glucose, supplemented with various 
treatments (1mM tryptophan, 5µM IAA, 50µM IAA or 500µM IAA), and grown statically in 
a 96-well plate covered with breatheable tape in place (Brethe-EASIER, Diversified 
Biotech), at 28°C for 72 hours [70]. After 72 hours, adherent cells were rinsed with water, 
patted dry and stained with 0.1% w/v crystal violet stain for 10 minutes at room 
temperature. The stain was then poured off and plates were washed 2 times with water, 
patted dry and air dried for 30 minutes. After drying, the crystal violet associated with 
biofilms was dissolved using, 200µl per well, a modified biofilm dissolving solution which 
contained 10% w/v SDS dissolved in 80% v/v ethanol and incubated at room temperature 
for 10 minutes [101]. Absorbance was measured at 550 nm using a BioTekSynergy 2 
microplate reader.  
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Chapter 3 
Results  
 
3.1 Identification of putative IAA biosynthetic enzymes by genomic analyses 
Our previous work showed that Pantoea sp. YR343 produces IAA following addition of 
tryptophan to the growth medium [70].  A number of tryptophan-dependent biosynthetic 
pathways for IAA have been described in microbes, Figure 1.4; [74].  To determine which 
pathway(s) may be present in Pantoea sp. YR343, we performed genomic analyses to 
identify putative homologs of known proteins in these pathways.  From these analyses, 
we were able to clearly identify an ipdC homolog (PMI39_00059), which encodes indole-
3-pyruvate decarboxylase, an enzyme in the IPA pathway.  The first step in the IPA 
pathway (Trp→indole-3-pyruvate) requires aromatic aminotransferase function and we 
identified seven genes in Pantoea sp. YR343 that are annotated to encode gene products 
with this function, Table 3.1.  Likewise, the final step in this pathway (indole-3-
acetaldehyde (IAAld) →IAA) requires an aldehyde dehydrogenase and there are at least 
17 gene products annotated with this function, Table 3.1. These results suggest that 
Pantoea sp. YR343 may have a functional IPA pathway.  
Similarly, we analyzed the genome for the presence of gene products found in the other 
IAA biosynthetic pathways. Because we were unable to find a homolog of tryptophan 
monooxygenase, we ruled out the presence of the IAM pathway in Pantoea sp. YR343, 
Figure 1.3.  Likewise, Pantoea sp. YR343 lacked enzymes in the IAN pathway, Figure 
1.3.  Because the TSO pathway has only been described in Pseudomonas florescens 
CHA0 [102], we concluded that its presence in Pantoea sp. YR343 seemed unlikely. 
Although the sequence homologies were low, we did find genes encoding candidate 
enzymes in the tryptamine pathway, suggesting that this pathway may also be present in 
Pantoea sp. YR343.  
3.2 Proteomics of Pantoea sp. YR343 grown in the presence of tryptophan 
To better understand how Pantoea sp. YR343 synthesizes IAA, we generated proteomic 
profiles of cells growing in the presence or absence of tryptophan.  We detected 2046 
proteins from cultures grown in the presence of tryptophan, with 20 proteins that were 
significantly differentially abundant under these growth conditions, Table 3.2, Figure 3.1C.  
Not surprisingly, we found that several enzymes in the tryptophan biosynthesis pathway 
(encoded by PMI39_02719-PMI39_02724) were downregulated in the presence of 
excess tryptophan.  Conversely, none of the enzymes predicted to be involved in IAA 
biosynthesis showed statistically significant differences in abundance in the presence of 
tryptophan, Table 3.1.  Despite the results not being statistically significant (p=0.06), IpdC 
did trend toward being more abundant in the presence of excess tryptophan. These 
results also showed that only four of the seven predicted aromatic aminotransferases in 
the IPA pathway were detected under these growth conditions, Table 3.1.  Likewise, only 
9 out of 17 predicted aldehyde dehydrogenases were detected, Table 3.1.  In the 
tryptamine pathway, only one out of the two enzymes was detected under these growth 
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Table 3.1. Candidate enzymes in the IAA biosynthetic pathways of Pantoea sp. YR343.  
Ratios are based on normalized spectral abundance factors (NSAF) and are calculated 
as the log2 ratio of experimental condition to control (minimal media). Ratios that are 
highlighted are statistically significant. ND indicates that the protein was not detected 
under these conditions.  
 
Candidate Tryptophan Dependent Enzymes 
IPA Pathway 
Locus Tag Trp  5µM IAA  50µM IAA  500µM IAA  
Aromatic Aminotransferases 
PMI39_01811 0.8487 0.4171 0.7565 1.0798 
PMI39_01993 0.2275 0.0713 0.3541 -0.2875 
PMI39_02094 -1.3658 -2.0033 -0.9197 -3.2724 
PMI39_02628 ND 2.5612 1.5838 1.6159 
PMI39_02920 ND ND ND ND 
PMI39_04274 ND -0.0348 -0.0686 1.6159 
PMI39_04560 0.6005 0.7075 0.1988 1.1081 
ipdC 
PMI39_00059 5.1663 -0.0348 1.8268 3.9062 
Aldehyde Dehydrogenases 
PMI39_00313 ND ND ND ND 
PMI39_00317 ND ND ND ND 
PMI39_00354 -0.4284 0.31 0.3592 0.1593 
PMI39_00431 ND ND ND ND 
PMI39_00617 -0.706 -1.9921 0.3006 1.0616 
PMI39_00725 ND 1.6233 2.567 2.0691 
PMI39_00794 ND 1.4607 -0.0686 0.1916 
PMI39_00977 ND ND ND ND 
PMI39_01356 ND 2.2756 -0.0686 0.1916 
PMI39_02144 -0.0257 1.1257 1.6944 0.9253 
PMI39_02889 0.6333 0.2894 0.3945 1.3988 
PMI39_03367 -0.6096 -0.4069 -0.2181 0.5863 
PMI39_03939 ND ND ND ND 
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Table 3.1 Continued    
Locus Tag Trp  5µM IAA  50µM IAA  500µM IAA  
PMI39_04111 0.3855 0.0882 0.5504 0.4438 
PMI39_04199 -1.2084 -1.4993 1.0188 -1.2728 
PMI39_04201 -1.2818 -1.5726 -1.6064 -1.3461 
PMI39_04236 -0.0178 0.0281 -0.1852 0.2146 
Tryptamine Pathway 
PMI39_03119 
PMI39_03409 
-0.2738 
ND 
1.854 
-0.0348 
1.854 
-0.0348 
2.4726 
3.3216 
Note: ND = Not Detected, highlighted grey = Statistically Significant 
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Table 3.2. Proteins that are differentially expressed in the presence of tryptophan.  The 
log2ratio is based on the normalized spectral abundance factor (NSAF) and is shows as 
the log2 ratio of trp to control.  
 
Proteins that are Statistically Differentially Abundant in the Presence Of Tryptophan 
Locus Tag Predicted Function  Trp 
PMI39_04926 ATPase-P-type (transporting), HAD superfamily, subfamily IC 3.9928 
PMI39_00980 Octopine/nopaline transport system substrate-binding protein 3.9589 
PMI39_04398 Protein of unknown function 3.9413 
PMI39_01931 Hypothetical protein 3.8306 
PMI39_01840 Glycosyltransferase involved in cell wall biosynthesis 3.1865 
PMI39_00879 UFP0755 protein 2.9928 
PMI39_03779 2-isopropylmalate synthase -0.7728 
PMI39_01718 4-aminobutyrate aminotransferase -1.0498 
PMI39_00111 ABC-type uncharacterized transport system, periplasmic component -2.481 
PMI39_03872 B3/B4 domain-containing protein -2.481 
PMI39_03883 Transcriptional regulator, TetR family -2.481 
PMI39_01285 Hypothetical protein -2.705 
PMI39_00349 Transcriptional regulator, ArgR family -2.885 
PMI39_04501 Glucose-1-phosphate adenylytransferase -3.2081 
PMI39_04638 Membrane dipeptidase -3.2081 
PMI39_02719 Anthranilate synthase, component I -3.3475 
PMI39_00256 DNA repair protein RadA/Sms -3.4718 
PMI39_02040 Polar amino acid tranprot system substrate-binding protein -3.8029 
PMI39_02676 Hypothetical protein -3.9673 
PMI39_02215 Branched-chain amino acid transport system substrate-binding protein -4.2136 
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Figure 3.1: Growth curves of Pantoea sp. In various conditions. A) Various concentrations 
of exogenous tryptophan. B) Various concentrations of exogenous IAA. 
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conditions, Table 3.1 
3.3 Proteomics of Pantoea sp. YR343 grown in the presence of IAA 
Because IAA itself can cause changes in growth of P. dispersa [68]and act as a positive 
regulator of ipdC gene expression in A. brasilense [76, 81], we wanted to determine the 
effects of IAA exposure on Pantoea sp. YR343.  For this experiment, we grew Pantoea 
sp. YR343 in minimal medium supplemented with 5µM, 50µM, or 500µM IAA.  Unlike the 
results with P. dispersa [68], we did not observe any differences in the growth of Pantoea 
sp. YR343 cultures in different concentrations of IAA, Figure 3.1.  In addition, Panteoa 
sp. YR343 was not able to grow using IAA as the sole carbon source (data not shown).  
Despite no observable differences in growth, proteomics analyses revealed many 
differentially abundant proteins under these growth conditions, Table 3.3, and Figure 3.2 
A,B,C,D).  In these experiments, we detected 2437 proteins across all runs (5μM, 50μM, 
and 500µM IAA). In the cultures grown with 5μM IAA, we detected 34 statistically 
differentially expressed proteins compared to cells grown in minimal medium, Table 3.3. 
In cultures grown with 50μM and 500μM IAA, we detected 26 and 55 statistically 
differentially expressed proteins, respectively, Table 3.3.  
Among the proteins that are differentially regulated, we found several proteins involved in 
phosphate regulation, including PhoU (PMI39_02797) and PhoH (PMI39_02138) which 
are both upregulated, and PstB (PMI39_03605) which is down-regulated.  In many 
bacterial systems, PhoU acts as a negative regulator of PhoR, which, together with PhoB, 
forms a two-component regulatory system that modulates the cellular response to 
environmental phosphate levels [103]. PhoU also plays a role in regulating the phosphate-
specific transporter Pst (PstSCAB), of which PstB is a component [104, 105]. Several 
proteins involved in inorganic ion transport and metabolism were also upregulated, 
including two involved in iron transport, (PMI39_01007, PMI39_04647), an ABC-type 
molybdenum transporter (PMI39_04031), and a copper binding protein (PMI39_04844).   
A number of proteins involved in carbohydrate (PMI39_00875, PMI39_02090; 
PMI39_03310) and amino acid (PMI39_00875, PMI39_02090; PMI39_03310) transport 
and metabolism were also more abundant in the presence of IAA.  In addition, we also 
observed upregulation of PMI39_00356 which has homology to E. coli AaeA, a protein 
involved in aromatic carboxylic acid efflux [106].  It has been noted that AaeA and other 
efflux pump proteins are highly active in bacterial biofilms [107].  Growth in the presence 
of IAA also resulted in upregulation of the gene product encoded by PMI39_01840, which 
is part of a conserved operon involved in EPS biosynthesis (PMI39_1848-PMI39_01821). 
Other gene products in that operon were also upregulated, although their abundance was 
not statistically significant.  In Erwinia amylovora and P. stewartii, the gene products 
encoded by this operon are required for the synthesis of an acidic extracellular 
polysaccharide, named amylovoran or stewartin, respectively [108, 109]. 
Enzymes predicted to play a role in IAA biosynthesis were differentially abundant in the 
presence of IAA, including IpdC (PMI39_00059) which was significantly more abundant 
when cells were grown in 500 μM IAA, Table 3.1 and 3.3. Of the seven predicted aromatic 
aminotransferases in the IPA pathway, we detected six when cells were grown in the 
presence of IAA.  Likewise, we detected 12 of the 17 predicted aldehyde dehydrogenases  
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Table 3.3. Proteins that are differentially expressed in Pantoea sp. YR343 with exogenous 
IAA (5µM, 50µM, and 500µM).  The log2ratio is based on the normalized spectral 
abundance factor (NSAF) and is shows as the log2 ratio of trp to control. 
 
Indole-3-Acetic Acid Statistically Significant Proteins 
LocusTag Predicted Function 5µM  50µM  500µM  
PMI39_01856 Porin, OprB family 1.4607 -0.0686 5.7262 
PMI39_01007 Ferritin 3.9464 4.0749 4.914 
PMI39_04656 NADP-dependent 3-hydroxy acid dehydrogenase YdfG -0.0348 -0.0686 4.8976 
PMI39_03310 Simple sugar transport system substrate-binding -0.0348 2.0704 4.6733 
PMI39_02999 3-oxoacyl-(acyl-carrier-protein) synthase 3.9491 3.2246 4.5582 
PMI39_01826 Hypothetical Protein 3.6444 3.5317 4.4485 
PMI39_04053 2-keto-4-pentenoate hydratase -0.0348 -0.0686 4.2681 
PMI39_01840 Glycosyltransferase involved in cell wall bisynthesis 3.7732 2.9993 4.118 
PMI39_04447 Hypothetical Protein 1.9249 2.8686 3.9337 
PMI39_03722 ABC-type multidrug transport system, ATPase  3.5185 2.6527 3.9062 
PMI39_00059 Indolepyruvate decarboxylase -0.0348 1.8268 3.9061 
PMI39_00367 Sulfoxide reductase catalytic subunit YedY 3.9026 3.8041 3.8836 
PMI39_01901 S-formylglutathione hydrolase FrmB 3.7233 3.2893 3.8043 
PMI39_03606 Phosphoribosylglycinamide formyltransferase-1 2.2421 2.567 3.8043 
PMI39_02797 Phosphate transport system protein 2.9169 3.1951 3.7987 
PMI39_00352 Protein of unknown function  1.393 3.5549 3.6965 
PMI39_01997 Hypothetical Protein 1.393 2.4336 3.6702 
PMI39_01799 Putative dehydrogenase  2.6077 -0.0686 3.629 
PMI39_04031 Molybdate transport system, ATP-binding protein  2.8853 3.0588 3.5427 
PMI39_01989 NADH dehydrogenase subunit B 1.8468 1.4219 3.5203 
PMI39_00126 Transcriptional regulator, RpiR family 2.8494 -0.0686 3.5202 
PMI39_00132 RNAse III 2.1383 2.2112 3.4907 
PMI39_04844 Hypothetical Protein 2.9169 2.5443 3.4907 
PMI39_00980 Octopinne/nopaline transport system  -0.0348 -0.0686 3.4837 
PMI39_00202 CDP-diacylglycerol-serine O-phosphatidyltransferase 2.8997 2.4336 3.4604 
PMI39_00847 Phosphatase NudJ 3.702 4.375 3.4604 
PMI39_01851 dCTP deaminase 1.4607 2.7951 3.3376 
PMI39_00356 p-hydroxybenzoic acid efflux pump subunit AaeA 1.4096 2.1012 3.3298 
PMI39_01459 Putative Toxin-antitoxin system antitoxin component 1.8468 2.5207 3.3039 
PMI39_04094 D-serine deaminase, pyridoxal phosphate-dependent -0.0348 1.4219 3.3039 
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Table 3.3 Continued 
LocusTag Predicted Function 5µM  50µM  500µM  
PMI39_00821 Integration host factor subunit alpha  2.2801 1.3711 3.1284 
PMI39_02138 Phosphate starvation-inducible protein PhoH -0.0348 1.4219 3.1284 
PMI39_04745 Membrane-bound inhibitor of C-type lysozyme 3.3853 3.2056 3.1284 
PMI39_02976 Lysophospholipase, alpha-beta hydrolase superfamily 1.8468 1.4219 3.1284 
PMI39_02719 Anthranilate synthase, component I 1.3768 1.9522 2.676 
PMI39_04394 Glycerol kinase -0.1381 0.0453 2.6406 
PMI39_03735 Aconitase  0.165 0.6411 1.8773 
PMI39_02092 Gluconate 2-dehydrogenase 0.5738 0.3469 1.4872 
PMI39_02090 2-dehydro-3-deoxygluconokinase  -0.0857 -0.0329 1.4689 
PMI39_00875 PST system D-glucose-specific IIB component, Glc  0.9118 0.5602 1.2818 
PMI39_02763 Threonine dehydratase 0.8239 1.205 1.1246 
PMI39_00913 Glutaredoxin 2 -0.2758 -0.1577 -1.3042 
PMI39_01963 Hypothetical Protein -0.1487 -0.1923 -2.7535 
PMI39_00828 Hypothetical Protein -0.4603 -1.1449 -2.7802 
PMI39_01027 Fimbrial chaperone protein 0.6939 0.3742 -2.9354 
PMI39_03605 Phosphate transport system ATP-binding protein  -1.5037 -3.1957 -2.9354 
PMI39_02043 Amino acid ABC transporter ATP-binding protein -3.1896 -3.2234 -2.9631 
PMI39_02823 Two-component system, OmpR family -0.1859 -0.1162 -3.1303 
PMI39_04666 Uncharacterized conserved protein, DUF1778 family -3.3652 -0.4617 -3.1387 
PMI39_02094 DNA-binding transcriptional regulator, MocR family -2.0033 -0.9197 -3.2724 
PMI39_03268 S-adenosylhomocysteine hydrolase 0.2842 0.2237 -3.28 
PMI39_02182 Flagellar FliL protein -0.2213 -1.1131 -3.4048 
PMI39_02311 5-hydroxyisourate hydrolase -1.0599 -1.3599 -3.567 
PMI39_01065 3,4-dihydroxy-2-butanone 4-phosphate synthase -0.0869 -1.9795 -3.6733 
PMI39_00743 Nicotinamidase-related amidase 0.0547 -0.8319 -3.865 
PMI39_02040 Polar amino acid transport system substrate-binding  -1.1558 -4.1275 -3.8672 
PMI39_03037 Protein of unknown function  -0.4099 -1.036 -4.0671 
PMI39_01330 Nitrogen regulatory protein P-II family -0.636 -1.0404 -4.2146 
PMI39_00439 GTPases-translational elongation factors 0.6619 0.0105 -6.1693 
PMI39_01931 Hypothetical Protein 2.2756 4.168 3.3724 
PMI39_00919 N-methyl-L-tryptophan oxidase 4.0801 4.012 3.6056 
PMI39_04563 Predicted DNA-binding protein, MmcQ/YjbR family 1.4607 3.5317 1.7528 
PMI39_04190 SOS-response transcriptional repressor LexA  2.8853 3.4246 1.7917 
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Table 3.3 Continued 
LocusTag Predicted Function 5µM  50µM  500µM  
PMI39_03970 Glutamine amidotransferase 2.2756 3.3734 2.2711 
PMI39_01082 Hypothetical Protein -0.0348 3.0908 3.2954 
PMI39_00219 SIR2-like domain-containing protein 2.9026 3.0588 3.3425 
PMI39_03880 Predicted O-methyltransferase 1.9249 2.9182 2.6304 
PMI39_01725 Tat proofreading chaperone FdhE 3.0634 2.9182 2.0691 
PMI39_03657 Protein of unknown function  1.6233 2.9182 2.0691 
PMI39_04459 NADPH:quinone reductase  3.4238 2.882 4.2627 
PMI39_04877 Gallate dioxygenase -0.0348 2.882 2.935 
PMI39_02474 psiF repeat-containing protein -0.0348 2.882 0.1916 
PMI39_00140 L-aspartate oxidase 3.033 2.8713 3.9684 
PMI39_01922 Microcin C transport system ATP-binding protein 3.287 2.8713 2.7549 
PMI39_01022 DNA-binding transcriptional regulator, MocR family -0.0348 2.6683 1.6159 
PMI39_00836 Fe-S cluster assembly protein SufA -0.2913 -2.8056 0.2475 
PMI39_03702 Iron-sulfur cluster insertion apoprotein erpA -2.7718 -2.8056 -0.1065 
PMI39_00111 ABC-type uncharacterized transport system -2.7716 -2.8056 -0.3327 
PMI39_01285 Hypothetical Protein -2.9958 -3.0295 -0.5567 
PMI39_04680 Hypothetical Protein 4.1889 2.9921 0.1916 
PMI39_04926 ATPase, P-type (transporting), subfamily IC 4.0685 3.6001 4.1146 
PMI39_04795 Alanine racemase 3.5155 2.8686 3.5536 
PMI39_03844 Methyl-accepting chemotaxis sensory transducer 3.4139 1.8268 0.1916 
PMI39_01778 Lipopolysaccharide biosynthesis proteins 3.3874 -0.0686 0.1916 
PMI39_03122 Phosphoserine phosphatase 3.2582 2.4336 2.6913 
PMI39_04643 Iron complex outermembrane recepter protein  3.1359 2.4336 2.0691 
PMI39_03045 Putative transcriptional regulator 3.1359 2.1086 3.5536 
PMI39_01209 Lipoyl(octanoyl) transferase 3.1237 3.2893 1.6159 
PMI39_01125 16S rRNA C1402 (ribose-2'-O) methylase RsmI 3.1237 1.5838 1.6159 
PMI39_02390 DNA recombination protein RmuC 2.9533 1.8854 2.6835 
PMI39_02372 ATP-dependent DNA helicase UvrD 2.9533 1.5838 3.1719 
PMI39_04744 Pyridoxamine 5'-phosphate oxidase 2.9533 1.4219 2.4135 
PMI39_00174 Restriction endonuclease 2.9169 2.9993 2.2267 
PMI39_04894 DNA gyrase inhibitor  2.9026 -0.0686 2.4135 
PMI39_00549 Formate transporter 2.702 2.8578 0.1916 
PMI39_04198 DNA-binding transcriptional regulator, LysR family 2.702 2.7235 1.7528 
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Table 3.3 Continued 
LocusTag Predicted Function 5µM  50µM  500µM  
PMI39_03751 GMP reductase 1.5402 1.1401 1.1029 
PMI39_02489 Recombination associated protein RdgC 1.1117 0.7819 0.6966 
PMI39_04647 lysine/arginine/ornithine transport system  -3.1619 0.2718 0.6472 
PMI39_01157 Hypothetical Protein -3.3567 -0.7548 -0.9177 
PMI39_03855 Enamine deaminase RidA, YjgF/YER057c/UK114 family -3.7626 -1.0875 -2.1118 
PMI39_04118 Peptide/nickel transport system substrate-binding  -4.6936 -0.1795 1.1454 
Note: Highlighted Grey = Statistically Significant  
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Figure 3.2. Volcano plot illustrates significantly differentially abundant proteins in Pantoea 
sp. YR343 in the present of tryptophan or IAA. The -log10  (Benjamini-Hochberg corrected 
P value) is plotted against the log2 (Fold change). A) Tryptophan B) 5µM IAA (1µg) C) 
50µM IAA (10µg) D) 500µM IAA (100µg).  
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under these growth conditions, Table 3.1.  Both enzymes predicted to play a role in the 
tryptamine pathway were also detected under these conditions.   
3.4 Induction of ipdC gene expression 
The proteomics analysis suggests that IpdC is more abundant in the presence of excess 
tryptophan and high levels of IAA.  To determine whether ipdC gene expression is 
upregulated under these conditions, we constructed a reporter plasmid (pPROBE-ipdC) 
in which GFP expression is controlled by the ipdC promoter.  After transforming this 
plasmid into wildtype Pantoea sp. YR343, we grew cultures in the presence of tryptophan 
or IAA and measured GFP fluorescence compared to control cultures.  These results 
showed that the ipdC promoter was activated in the presence of both tryptophan and IAA, 
Figure 3.3.  An increase in ipdC gene expression in the presence of excess tryptophan 
was confirmed using RT-PCR, which showed a 1.3 fold induction, Figure 3.3.   
3.5 Characterization of an ipdC mutant strain 
Combined, these data suggest that the IPA pathway is the major IAA biosynthesis 
pathway in Pantoea sp. YR343 and that IpdC expression is induced in the presence of 
tryptophan and IAA.  To confirm this, we constructed a mutant strain of Pantoea sp. 
YR343 in which the ipdC gene was disrupted.  This mutant did not show any defects in 
growth on plates or in liquid cultures (data not shown).  Wildtype and ΔipdC mutant cells 
were grown in minimal media overnight, the cells were removed by centrifugation, and 
the supernatant was analyzed by GC-MS to determine the metabolite profile.  According 
to this analysis, the dominant metabolites in wildtype cells were indole-3-pyruvate, 
tryptophol, and IAA, with minor peaks representing indole-3-lactate, and indole-3-
carboxyaldehyde (Figure 3.4).  Using deuterated-IAA as a standard, these analyses 
indicate that the wildtype cells produced approximately 2.5µg/ml IAA.  Tryptophol is 
produced by the reduction of indole-3-acetaldehyde (IAAld) while oxidation of IAAld 
produces IAA. IAAld was not detected in the supernatants because the conversion from 
IAAld to tryptophol is extremely rapid.  This metabolite profile is consistent with an active 
IPA pathway.  Moreover, we did not detect any indole-3-acetamide (IAM) or indole-3-
acetonitrile (IAN) which would be expected if the IAM or IAN pathways were active in 
Pantoea sp. YR343.  Likewise, we prepared samples using a base extraction method, as 
described in the methods, to look for production of tryptamine but we did not detect this 
metabolite, suggesting that the tryptamine pathway is not active in Pantoea sp. YR343. 
To ensure tryptamine was not being trapped inside of the cells we also did a whole cell 
extraction and did not detect this metabolite, again suggesting the tryptamine pathway is 
not active in Pantoea sp. YR343 in the presence of tryptophan, Figure 3.4. Additionally, 
in the tryptamine extraction we also did not detect any other indolic compounds, the 
representative peaks are residual acids phenyls, Figure 3.4.   
Due to the absence of ipdC, the mutant cells showed a different metabolite profile, with 
the dominant metabolites being indole-3-pyruvate and indole-3-lactate, Figure 3.5.  
Tryptophol was completely absent in the supernatant from these mutant cells.  Since 
tryptophol is produced from IAAld, we conclude that the ΔipdC mutant lacks indole 
pyruvate decarboxylase activity and is unable to produce IAAld.  Interestingly, however, 
we did detect some IAA in the mutant cells, albeit at much lower levels compared to wild 
type cells (500 ng/ml).  As in the wildtype cells, we also failed to detect tryptamine, IAN, 
and IAM in the supernatant from mutant cells.  Thus, detection of IAA was unexpected 
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since our genomic, proteomic, and metabolomic data was consistent with the IPA 
pathway being the only active biosynthetic pathway in Pantoea sp. YR343.  The presence 
of IAA in the supernatant from the mutant could certainly suggest that IAA is being 
synthesized by Pantoea sp. YR343, either by an unidentified pathway or one that was 
erroneously ruled out.  It has been noted, however, that IPA is unstable and can 
spontaneously degrade to IAA [110].  To test whether this may be happening in our 
samples, we grew cultures of wildtype cells, removed the cells by centrifugation, and 
collected the supernatant.  The supernatant was split into two aliquots, with one aliquot 
being analyzed by GC-MS immediately and the other aliquot incubated for an additional 
24 hours before GC-MS analyses.  In the aliquot that was analyzed immediately, IPA was 
found at about 100µg/ml and IAA at about 860ng/ml.  When the supernatant was 
incubated for an additional 24 hrs in the absence of cells, we saw a decrease in IPA to 3 
fold (about 30µg/ml) and an increase in IAA to 2 fold (about 2µg/ml), Figure 3.6. These 
data are consistent with the spontaneous degradation of IPA into IAA and may explain 
the accumulation of the IAA in the ΔipdC mutant.  
3.6 Loss of IpdC activity does not impair root colonization or biofilm formation 
Finally, we investigated whether loss of the ipdC gene affects other biological behaviors 
such as plant colonization and biofilm formation. Inactivation of the IPA pathway in 
Pantoea sp. YR343 influenced its ability to associate with plants.  The results of these 
experiments showed that the ΔipdC mutant was able to colonize poplar roots as efficiently 
as the wildtype cells, Figure 3.7 (A).  These data suggest that microbial production of IAA 
is not required to initiate plant association by Pantoea sp. YR343. Next, we examined the 
ability of wild type and ΔipdC cells to form biofilms. Using the 96-well plate assay, we 
found that the ΔipdC was not deficient in biofilm formation, Figure 3.7 (B). We also noticed 
that biofilm formation was not affected by various concentrations of IAA. More importantly 
we noticed that biofilm formation was increased in the presence of tryptophan for both 
WT and ΔipdC. These data suggest that the ipdC gene is not required to initiate biofilm 
formation by Pantoea sp. YR343. 
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Figure 3.3. ipdC gene expression in Pantoea sp. YR343. Confocal images of pPROBE-
ipdC reporter plasmid (A) without tryptophan (B) with tryptophan and (C) with 50µM IAA. 
D) Quantification of pPROBE-ipdC fluorescence (Control, trp, 5µM, 50µM, and 500µM) 
by confocal microscopy. E) Transcriptomics (RT-PCR) of Pantoea sp. YR343 with and 
without tryptophan, using 16s as a negative control.  
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Figure 3.4: Representative chromatograms of Pantoea sp. YR343, WT and ΔipdC using 
a basic extraction to identify tryptamine. A) WT supernatant extraction. B) WT whole cell 
extraction. C) ΔipdC supernatant extraction. D) ΔipdC whole cell extraction.  
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Figure 3.5. Representative metabolomics of Pantoea sp. YR343 and Pantoea sp. YR343 
ΔipdC. A) Complete chromatogram B) Tryptophol chromatogram C) IAA chromatogram. 
IAA was signally (m/z 130.1) and doubly (m/z 202.1) derivatized giving two peaks. D) 
Tryptophol spectra E) IPA spectra F) IAA 130.1 signly derivatized spectra G) IAA 202.1 
doubly derivatized spectra. Indolic compound prediction was based on the precursor ion 
mass and fragmentation patterns through NIST.     
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Figure 3.6. Representative metabolomics of spontaneous degradation of IPA in Pantoea 
sp. YR343 and Pantoea sp. YR343 ΔipdC after 2 days. (A) Complete chromatogram of 
day 1 and day 2 (B) Chromatogram of IPA alone both day 1 and day 2 (C) Chromatogram 
of IAA on both day 1 and day 2. IAA was signaly (m/z 130.1) and doubly (m/z 202.1) 
derivatized giving two peaks. Indolic compound prediction was based on the precursor 
ion mass and fragmentation patterns through NIST. 
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Figure 3.7: Pantoea sp. YR343 (WT and ΔipdC). A) Populus deltoides root colonization 
assay by wild type Pantoea sp. YR343 and ΔipdC is described as the Log10 value of 
colony forming units (CFUs) per gram of root material. B) Comparison of biofilm formation 
between wild type Pantoea sp. YR343 and the ΔipdC in a plastic 96-well plate measured 
by the crystal violet assay, as described in the methods   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
Chapter 4 
Discussion 
 
In this dissertation, we use a combination of genomic, transcriptomic, metabolomic, and 
proteomic analyses to investigate the biosynthesis of IAA by Pantoea sp. YR343.  The 
production of IAA by some microbes has been associated with their plant growth 
promoting behavior [65, 111-114]. In the case of P. agglomerans, this growth promotion 
is thought to be due to enhanced root architecture, which, in turn, can result in enhanced 
water and nutrient uptake by the plant. The microbe benefits from this interaction by 
access to nutrients found in plant exudate, as well as increased surface area for 
colonization.  A number of biosynthetic pathways have been described in microbes for 
IAA production.  The ability to assign specific gene products to these pathways using 
genomic analyses, however, is limited to only a few well-characterized enzymes, such as 
IpdC and trp monooxygenase. Other steps in these IAA synthesis pathways are defined 
by general functions such as aromatic aminotransferase and aldehyde dehydrogenase, 
and most bacterial genomes contain many candidate gene products with these annotated 
functions.  Determining which of these candidate gene products is more likely to be 
involved in IAA biosynthesis is further hindered by the fact that few of the IAA biosynthetic 
enzymes appear to be co-expressed in operons.  Thus, genomic analyses can provide 
an inventory of candidate gene products, but additional experimentation and/or molecular 
modeling is required to determine whether these gene products may be involved in IAA 
biosynthesis. 
 In Pantoea sp. YR343, genomics analyses identified 7 candidate aromatic 
aminotransferases and 17 candidate aldehyde dehydrogenases that catalyze steps in the 
IPA pathway, of which only 4 aminotransferases and 9 aldehyde dehydrogenases were 
detected by proteomics during growth under conditions (excess trp) in which IAA is 
produced.  Based on the basic assumption that enzymes involved in IAA biosynthesis 
should be present under conditions in which cells are producing IAA, the proteins that 
were identified in our proteomics analyses are more likely to be involved in IAA 
biosynthesis. It should be noted, however, that none of the enzymes was particularly 
abundant and the relevant enzymes may be present in cells but not detected in this 
analysis.  Nevertheless, the proteomic results serve to prioritize which enzymes are 
selected for future analyses. IpdC, on the other hand, was more abundant in the presence 
of trp and IAA, suggesting that its expression is regulated.  Indeed, we found that the ipdC 
promoter is activated in the presence of both trp and IAA. How ipdC gene expression is 
regulated will be the subject of future studies.  Collectively, these data point to a model in 
which IAA biosynthesis in Pantoea sp. YR343 proceeds via the IPA pathway and is 
regulated by ipdC expression.     
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To better understand the changes to the proteome in the presence of IAA, we grew 
Panteoa sp. YR343 in 5µM, 50 µM or 500 µM IAA. The localized concentration of IAA 
typically experienced by Panteoa sp. YR343 in the rhizosphere is currently unknown and 
determining this value presents a measurement challenge that will require advances in 
chemical imaging methods.  Interestingly, growth of Pantoea sp. YR343 under each of 
these conditions produced different sets of differentially abundant proteins.  Whether 
these conditions represent different stages in the initiation and maintenance of plant 
association is an intriguing possibility, although it is also possible that these results are a 
reflection of biological variation and instrument sensitivity.   
Taken together, it is clear that growth in the presence of IAA results in changes to the 
proteome in Pantoea sp. YR343.  These changes are reflected in upregulation of gene 
products associated with transport of carbohydrates, amino acids, and inorganic ions.  In 
particular, we see increases in proteins annotated to be involved in phosphate, 
molybdenum, iron, and copper metabolism.  Moreover, we see upregulation of gene 
products involved in EPS biosynthesis.  It is tempting to speculate that exposure to IAA 
induces changes in the physiology of Panteoa sp. YR343 that are advantageous for 
survival in the rhizosphere.  For example, sugars and amino acids are primary 
components of plant exudates; thus, upregulation of these transporters may allow 
Panteoa sp. YR343 to better compete for these resources.  Likewise, upregulation of EPS 
biosynthesis may promote attachment to plant roots and biofilm formation. 
Finally, the role of IAA in promoting plant-association was determined by construction of 
an ΔipdC mutant.  That indole pyruvate decarboxylase activity was disrupted was 
confirmed by metabolite analyses in which the mutant showed no accumulation of 
tryptophol, which is produced by reduction of IAAld.  Conversion of IAAld to tryptophol 
(reduction) or IAA (oxidation) is likely to be influenced by the redox state of the cell, with 
growth in minimal media with glucose favoring conversion to tryptophol.  In nutrient-
starved conditions, such as the rhizosphere, it is likely that conversion to IAAld to IAA is 
favored.  The absence of typtophol in the mutant also argued against the presence of an 
active tryptamine pathway since this pathway also produces IAAld.  Nevertheless, we did 
detect some IAA (approximately 20% of wildtype) in the supernatant of the ΔipdC mutant.  
The simplest explanation for the presence of IAA is that Pantoea sp. YR343 harbors more 
than one pathway for IAA biosynthesis, as has been found in other bacteria [74].  While 
we cannot say definitively that Pantoea sp. YR343 has more than one pathway, our 
genomic and metabolite data argue against this possibility.  Rather, we favor the alternate 
explanation that IAA is produced in the mutant by non-enzymatic degradation of indole 
pyruvate under these experimental conditions.  Indeed, our experiments show that 
extended incubation of supernatant collected from Pantoea sp. YR343 results in 
decreasing levels of indole pyruvate and increasing levels of IAA.   
Finally, we investigated whether disrupting IpdC function had any effect on the ability of 
Pantoea sp. YR343 to colonize poplar roots.  Perhaps surprisingly, we found that ΔipdC 
mutant cells were able to associate with poplar roots and form biofilms as efficiently as 
wildtype cells, suggesting that IAA is not likely required for initial attachment to the root 
or biofilm formation.  Alternatively, it is possible that another metabolite mediates this 
interaction or that the mutant is synthesizing IAA by an alternate pathway and this reduced 
amount of IAA compared to wildtype is sufficient to promote plant association. Another 
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possibility is that microbial IAA biosynthesis is triggered after plant association and is 
plays a role in the maintenance of plant-microbe interactions.  To better understand plant-
microbe association and distinguish between these possibilities, we will need to be able 
to measure the local concentration and spatial distribution of metabolites produced by 
microbes during plant association.  Indeed, identifying and measuring the temporal and 
spatial distribution of metabolites in complex systems is an exciting and challenging new 
area of research that will likely drive technical and scientific advances.  
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Chapter 5 
Conclusions and Future Directions  
 
Understanding biocomplexity within and between a multiorganismal system is a complex 
matter that requires a multitude of integrated omics approaches. In this dissertation, we 
presented findings from our omics study on the internal biochemical pathways of indole-
3-acetic acid (IAA) in the bacteria Pantoea sp. YR343. The essential findings of this 
dissertation can be summarized as follows: Data extracted from multiple omics 
approaches, lead to the novel discovery that the main pathway associated with IAA 
biosynthesis in Pantoea sp. YR343 is the indole-pyruvate pathway. The combination of 
existing experimental data from our omics results indicates that Pantoea sp. YR343 
produces about 2.5 µg of IAA per mL of culture, primarily through the indole pyruvate 
pathway. To confirm these results, we disrupted the ipdC gene in Pantoea sp. YR343 and 
analyzed its ability to produce IAA in the presence of tryptophan. We found that, 
empirically, disrupting the ipdC gene in Pantoea sp. YR343 dramatically reduced its ability 
to produce IAA in the presence of tryptophan. 
Using proteomics, we investigated Pantoea sp. YR343 response to exogenous IAA.  
Previous studies identified that IAA can act a positive regulator of the ipdC gene [76, 81], 
hence our next goal was to determine the effects of IAA exposure on Pantoea sp. YR343. 
Surprisingly, we found that at a very low concentration 50µM, more than 20 times less 
than observed in A. brasilense, we saw an increase of the ipdC gene expression, 
signifying IAA acts a positive regulator in Pantoea sp. YR343 [76]. More importantly, we 
noticed that the tryptophan biosynthesis genes were also differentially expressed in our 
IAA samples, indicating that when exposed to IAA Pantoea sp. YR343 increases its 
tryptophan biosynthetic pathways to make IAA.  
Another important observation was that apart from the genes involved in IAA biosynthesis 
(ex ipdC), several other proteins were also differentially expressed. In particular, we found 
pathways associated with phosphate regulation, inorganic ion transport and metabolism, 
carbohydrate and amino acid transport and metabolism, and aromatic carboxylic acid 
efflux, all of which could be essential characteristics for bacterial survival in the 
rhizosphere.  
Omics has become an indispensable approach to the studying of biological functions 
within complex biological ecosystems, specifically in plant-microbe associations. The 
omics approach in this dissertation allowed us to monitor Pantoea sp. YR343 under 
various external stimuli, revealing specific biosynthetic pathways associated with IAA 
production in Pantoea sp. YR343. We also showed that given a certain stimuli Pantoea 
sp. YR343 proteome changes which may ultimately influence how it responds in the 
environment given certain ques. The findings presented here only look at a one-
dimensional aspect of microbial interactions. Nevertheless, it is with certainty that we are 
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still just scratching the surface of understanding these complex biochemical interactions 
in Pantoea sp. YR343, let alone the plant-microbe associations on a large scale.  
The data presented in this dissertation calls for a new state of mind to consider the 
relationship between Pantoea sp. YR343 and its associated plant host, P. deltodies. 
Predicting IAA was a contributing phytohormone facilitating colonization between 
Pantoea sp. YR343 and P. deltodies, we performed colonization tests with our mutant 
deficient in IAA and found that Pantoea sp. YR343 colonization to P. deltodies was not 
affected. This means that there are other biological implications or phytohormones that 
could be contributing to the colonization of Pantoea sp. YR343 to P. deltodies. 
Understanding what types of cues or biochemical responses drive these responses is a 
fundamental area of research that needs to be addressed. Indeed, identifying and 
measuring the temporal and spatial distribution of metabolites in complex systems is an 
exciting and challenging new area of research that will likely drive technical and scientific 
advances. Currently, it would be difficult to identify the localized concentration of IAA or 
other phytohormones expressed by Pantoea sp. YR343 in the presence of P. deltodies 
because both Pantoea sp. YR343 and P. deltodies are capable of producing a variety of 
metabolites.  
One approach to measuring the local concentration of the metabolites produced by both 
Pantoea sp. YR343 and P. deltodies we be to create a lab on a chip utilizing mass-
spectrometry-based monitoring in combination with a microfluidic platform [115]. A 
microfluidic platform harboring P. deltodies roots along with the bacterial inoculum can be 
developed. The uniqueness of such a platform would be the ability to collect rhizosphere 
materials through the 20µm ports which would allow us to perform live LC-MS-MS. This 
platform could help us detect enzymes and other phytohormones, which might give us 
clues as to how plants and microbes communicate. 
Increasing our understanding about bacterial colonization and the cues it utilizes from the 
environment would greatly improve our knowledge about the complexity between plant-
microbe environments. Large plant-microbe community studies have begun to uncover a 
variety of details about plant-microbe interconnectivity, but have ultimately been limited 
due to experimental analysis. Utilizing high-throughput technologies and creating new 
platforms will further the advancements in understanding the complexity within a plant-
microbe environment.  
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Abstract  
Polymerization of the Z variant alpha-1-antitrypsin (Z-1AT) results in the most common 
and severe form of form of 1AT deficiency (1ATD), a debilitating genetic disorder 
whose clinical manifestations range from asymptomatic to fatal liver or lung disease. As 
the altered conformation of Z-1AT and its attendant aggregation are responsible for 
pathogenesis, the polymerization process per se has become a major target for the 
development of therapeutics. Based on the ability of Z-1AT to aggregate by recruiting 
on its s4A cavity the reactive center loop (RCL) of another Z-1AT, we developed a high-
throughput screening assay that uses a modified 6-mer peptide mimicking the RCL to 
screen for inhibitors of Z-1AT polymer growth. A subset of a commercially available 
library of small compounds with MWs ranging from 300 to 700 Da was used to test the 
assay’s capabilities, and the inhibitor S-(4-nitrobenzyl)-6-thioguanosine was found. To 
validate S-(4-nitrobenzyl)-6-thioguanosine, an in silico strategy was pursued and the 
intermediate 1AT M* state modeled to allow molecular docking simulations, which 
explore various potential binding sites. Docking results predict that S-(4-nitrobenzyl)-6-
thioguanosine can bind at the s4A cavity or at the edge of β-sheet A. The former binding 
site would block RCL insertion whereas the latter site would prevent β-sheet A from 
expanding between s3A/s5A, and thus indirectly impede RCL binding. Altogether, our 
investigations have revealed a novel compound that specifically inhibits the formation of 
Z-1AT polymers, as well as in vitro and in silico strategies for identifying small molecules 
for treatment of 1ATD. 
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A.1 Introduction  
Human 1-antitrypsin (1AT) is the most abundant member of the serine protease 
inhibitor (SERPIN) family. It is a soluble 52-KDa glycoprotein synthesized primarily by 
hepatocytes and delivered to the lungs to accomplish its critical function: inactivation of 
the proteinase neutrophil elastase (NE), a mediator of alveolar destruction.(Brantly, 
Nukiwa, & Crystal, 1988) Defective folding, trafficking and secretion into the plasma of 
1AT are responsible for 1AT deficiency (1ATD).(Bibek Gooptu, Dickens, & Lomas, 
2014a; Perlmutter, 2011)  
The structural flexibility of 1AT is important for it to perform its anti-protease function and 
ensure lung integrity. With a core domain composed of 3 -sheets A, B and C, and 9 -
helices, 1AT features an exposed and flexible reactive center loop (RCL) that serves as 
bait for NE. Upon binding to the proteinase, a dramatic conformational change occurs as 
RCL is cleaved and translocates into -sheet A to form the new central and fourth strand, 
s4A. The translocation event carries along NE from one side to the other of 1AT, causing 
its inactivation by forming an irreversible, higher molecular weight suicide 
complex.(Huntington, Read, & Carrell, 2000),(Whisstock & Bottomley, 2006) A reduction 
or lack of this inhibition through loop-sheet insertion and proteolytic cleavage is thought 
to be the underlying mechanism responsible for 1ATD.(Dafforn, Mahadeva, Elliott, 
Sivasothy, & Lomas, 1999),(Lomas, 2000) 
Over 100 genetic variants of 1AT have been identified with the Z-type being responsible 
for the most common and severe form of the disease in homozygous patients(de Serres 
& Blanco, 2012). The punctual mutation E342K in Z-1AT renders the anti-protease 
prone to aggregation and unable to be secreted into the blood stream resulting in a 90% 
decrease in NE inhibition within the lungs. Accumulation of polymers of Z-1AT in the 
endoplasmic reticulum (ER) of hepatocytes leads to proteotoxic stress and associated 
liver diseases.(An, Blomenkamp, Lindblad, & Teckman, 2005; Eriksson, Carlson, & Velez, 
1986; Hussain, Mieli-Vergani, & Mowat, 1991) In addition to sequestration of polymers in 
the ER of hepatocytes, the E342K mutation has two additional disease-causing effects. 
It causes Z-1AT to be 5-fold less effective in accomplishing its inhibitory function(Ogushi, 
Fells, Hubbard, Straus, & Crystal, 1987),(Lomas, Evans, Stone, Chang, & Carrell, 1993) 
and it promotes the spontaneous formation of Z-1AT polymers within the lungs, thereby 
further reducing the already depleted levels of 1AT that are available for alveola 
protection.(Elliott, Bilton, & Lomas, 1998) Moreover, the conversion of Z-1AT from a 
monomer to a polymer renders it a chemoattractant for human neutrophils.(Mahadeva et 
al., 2005),(Parmar et al., 2002) To summarize, emphysema associated with Z-1ATD 
results from a combination of (1) loss of function of the anti-protease, which leads to the 
absence of circulating 1AT, decrease of its inhibitory activity, and intra-alveolar 
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polymerization, and (2) gain of toxic function from the neutrophil chemotactic properties 
of intra-alveolar polymers. 
Preventing formation and accumulation of Z-1AT polymers could be crucial to treat 
1ATD.(Lomas, Perlmutter, & Uversky, 2010) For this reason, the mechanisms by which 
Z-1AT form polymers have been under intense investigation. As the substitution of the 
glutamic acid residue at position 342 by a lysine provokes a perturbation in the native 
structure by opening the -sheet A, biochemical evidence reveals the formation of an 
unstable and polymerogenic intermediate M* with its own RCL partially 
inserted.(Mahadeva, Dafforn, Carrell, & Lomas, 2002) The opening of the s4A cavity 
allows the creation of a sequential -strand linkage between the RCL of one serpin and 
-sheet A of another, leading to the formation of a dimer and then polymers.(Dafforn et 
al., 1999),(Ekeowa et al., 2010; B Gooptu et al., 2000; Purkayastha et al., 2005) Additional 
models for Z-1AT polymerization have also recently been proposed based on the crystal 
structures of a dimer of the serpin antithrombin(M Yamasaki, Li, Johnson, & Huntington, 
2008) and a trimer of a disulfide mutant of 1AT,(M Yamasaki, Sendall, Pearce, 
Whisstock, & Huntington, 2011) suggesting that assembly pathways of Z-1AT could be 
diverse and therefore arising from structurally and/or dynamically distinct polymerogenic 
intermediates. 
Various strategies have been pursued in order to prevent or even attenuate Z-1AT 
polymerization such as increasing the mutant protein secretion with the use of 
osmolytes(Burrows, Willis, & Perlmutter, 2000; Devlin, Parfrey, Tew, Lomas, & Bottomley, 
2001; Teckman, 2004) or by blocking Z-1AT polymerization by either filling the s4A 
cavity with peptides(Mahadeva et al., 2002) or crowding another hydrophobic pocket of 
Z-1AT with small compounds screened virtually.(Mallya et al., 2007) While extensive 
progress has been made, none of these strategies has been entirely successful so far.  
To achieve this goal, we developed a set of novel and integrated in vitro and in silico 
screenings methods; the in vitro, being a high-throughput screening assay using a 
modified small peptide previously reported as a s4A cavity filler,(Mahadeva et al., 2002) 
and the in silico being a virtual docking model able to predict and help rationalize the 
binding of compounds to 1AT, including in the S4A cavity.  Here, we present how using 
these two combined methods we were able to identify, rationalize and validate S-(4-
nitrobenzyl)-6-thioguanosine as a specific inhibitor of Z-1AT polymerization. 
A.2 Experimental procedures 
A.2.1. General materials and methods 
The peptide acetyl-FLEAIGGG-Q-GKKG containing the 6-mer sequence of the RCL was 
synthesized by custom solid-phase from the Keck Biotechnology Center at Yale 
University (http://info.med.yale.edu/wmkeck/).  A biotinylated version of the peptide 
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(bPEG-peptide) was obtained by appending a biotinyl-polyethylene glycol spacer on the 
-amide group of the glutaminyl residue. The presence of the Lys residues confer a 
positive net charge to the peptide at neutral pH, enhancing its general solubility. The wild 
type and Z-1AT proteins, prepared according to published protocol,(Parfrey et al., 2003) 
were graciously provided at a concentration of 1 mg/ml by Professor Lomas, Cambridge 
Institute for Medical Research, University of Cambridge, UK, and stored at 4 ºC. The 
rabbit anti-human 1AT antibody (serum fractions IgG) was purchased from Abcam, 
Cambridge, MA. 
The test group RK-001 of the LOPAC library (Library of Pharmacologically Active 
Compounds, Sigma-RBI, Natick, MA) containing 80 lyophilized chemical compounds was 
prepared in a 96-well plate format. All compounds were resuspended in 2 ml DMSO at a 
concentration of approximately 4 mM, based on an estimated MW average of 500 
g/moles, and stored at 4 ºC.  
A.2.2. Preparation of the bPEG-peptide 
The synthesized bPEG-peptide was first solubilized in 50% formic acid at a concentration 
of ~1mg/ml, injected onto a Zorbax C3 Column and purified by RP-HPLC at a rate of 
4ml/min. The resulting purified peptide was then lyophilized, resuspended into H2O and 
stored at -20 ºC. After amino acid analysis of the peptide (Commonwealth 
Biotechnologies Inc., Richmond, VA), various amounts were injected onto RP-HPLC in 
order to establish a standard curve, allowing us to determine the exact concentration of 
each new batch of purified peptide that we prepared. 
A.2.3. Preparation of working compound plates  
LOPAC compounds were transferred from their original 96-well plates to new 96-well 
working plates with low evaporation lid (BD Falcon plates non treated, Becton Dickinson 
Labware, San Jose, CA) in respect to their initial location, and adjusted to a concentration 
of 1 mM in PBS 1X containing 50% DMSO. First and last columns were filled only with 
PBS 1X/DMSO (50/50). Working plates were sealed with an adhesive overlay, covered 
and stored at 4º C until further utilization. 
A.2.4. Set up of the microplate screening assay 
The assay is based on the principle of a competitive ELISA.(Makarananda & Neal, 1992) 
Wells were coated by passive adsorption with a 1/1000 solution in PBS 1X of capture 
1AT Ab. The screening microplate was sealed with an adhesive overlay and incubated 
for 2 h at 37 ºC. The wells were then washed three times with extension buffer (PBS 1X 
and 0.01% Tween 20), blocked for 1 h at 37 ºC with 0.3 % gelatin and washed again. 
Screening results described in this paper were carried out with screening microplates 
freshly made. However, screening microplates can be filled with PBS 1X, hermetically 
sealed and stored at 4 ºC for one week prior to use. 
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A.2.5. Z-1AT polymerization inhibition assay 
In parallel with the preparation of the microplate screening assay, polymerization 
reactions were carried out in 96-well plates with or without the LOPAC small compounds. 
A 100 molar excess of bPEG-peptide was used with 4 g/well of Z-1AT.   
Each polymerization reaction plate was organized as follows: the first column contained 
only bPEG-peptide (background control); the second to eleven columns contained Z-
1AT, compounds and bPEG-peptide; and the last column contained Z-1AT, bPEG-
peptide and no compound (reaction control). Assay wells were set up by adding to each 
well 20 l of protein and 20 l of compound from a working plate. After 3 min, 160 l of 
bPEG-peptide at 48 M was added. The plate was then sealed, shaken on a microplate 
shaker gently for 5 s to ensure homogeneity of the different reactants, and placed at 37 
ºC for 16 h. All wells contained 5% DMSO. 
At the end of the 16 h incubation time, 100 l from each well were transferred into the 
corresponding well of the microplate screening assay. One hour later, the screening plate 
was washed three times and then incubated in the dark for 1 h at room temperature with 
100 l/well of 1 ng/l of europium streptavidin (Perkin Elmer, Boston, MA) in 0.5% BSA-
extension buffer. Three final washes in extension buffer were carried out and the 
europium was released from streptavidin by the addition of 100 l of enhancement 
solution (Perkin Elmer). After 5 min, europium fluorescence was measured by time-
resolved fluorometry in a Victor 2 counter (Perkin Elmer) and then converted to fmoles of 
bPEG-peptides recruited into Z-1AT. Assays were conducted in triplicate by processing 
three identical plates in parallel. 
A.2.6. Determining IC50 values of inhibitors  
As described above, 4 g/well of Z-1AT were incubated for 3 min with various 
concentrations of a compound identified as an inhibitor, the highest concentration starting 
at 400 M. The concentrations of the compounds were revised according to the true MW 
of the molecule. Following the 3 min incubation, 160 l of 48 M bPEG-peptide were 
added and the rest of the protocol was applied as described above. 
A.2.7. Z-1AT polymerization sedimentation assay  
A solution of 0.1 mg/ml of Z-1AT in PBS 1X was incubated at 37 ºC with or without 100 
M of S-(4-nitrobenzyl)-6-thioguanosine. Progress of the polymerization reaction was 
followed by quantitative RP-HPLC on centrifugation SUPERNANTANTS (20 min, 20,000 
× G) OF ALIQUOTES. Quantitative determination of the Z-1AT monomer 
disappearance was calculated according to a pre-established standard curve. 
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A.2.8. Preparing protein structures for homology modeling and docking simulations  
The crystal structures of the mutant Z-1AT (PDB code: 3T1P) and the wild type M-1AT  
(PDB codes: 3CWM and 1QLP) were obtained from the RCSB Protein Database.(Elliott, 
Pei, Dafforn, & Lomas, 2000; Pearce et al., 2008; M Yamasaki et al., 2011) Initial 
preparation of the receptor structures was carried out with the program MOE(“Chemical 
Computing Group - Citing MOE,” 2012) (Molecular Operating Environment). Co-
crystallized water molecules were deleted from both structures. For the polymerized 
mutant (3T1P), only the first monomer was retained and the s4A binding cavity was 
created between the s3A/s5A by deleting residues 345-356, which correspond to the 
inserted residues of the RCL. The protonation state of atoms was assigned using 
Protonate 3D(Labute, 2009) utility in MOE at pH 7, 300 K and 0.1 M salt concentration. 
Solvent effects were implicitly included by using a distance-dependent dielectric. Partial 
charges were assigned to receptor atoms using MMFF94s(Halgren, T. A. (1999) 
OBForceFieldMMFF94. J. Comput. Chem. 20, n.d.) force field parameters as 
implemented in MOE.  
A.2.9. Homology modeling procedure 
Modeling of the M* intermediate state as described below was performed using the 
Homology Model facility in MOE. The wild type crystal structure of 1AT (PDB code 
1QLP) was used as a template for modeling i) the position of the RCL when not inserted 
into β-sheet A and ii) the position of the c-terminal loop within β-sheet B when it is not 
participating in a domain swap. The polymerized Z-mutant structure (PDB code: 3T1P) 
was used to model the expanded position of β-sheet A but omitting s4A to leave a cavity 
between s3A/s5A where the RCL would otherwise be found. Fragments from each 
template structure were joined at transition points selected by superimposing the 
structures and choosing those residues between fragments with near overlapping atom 
positions. A total of 25 homology models were generated with unique carbon backbone 
positions, and for each of those 25 models, 5 additional models (i.e. a total of 125 models) 
were created with alternate side chain positions. These initial models were energy 
minimized to a gradient of 0.1 kcal/mol·Å. A final M* model (Model 126) was created using 
the Generalized Born / Volume Integral (GB/VI) energy scoring method(Labute, 2008) to 
select the best initially packed structure and then further energy minimizing it to a gradient 
of 0.01 kcal/mol·Å. 
A.2.10. Docking simulation procedure  
Three-dimensional structures of the 80 in vitro tested chemicals, including S-(4-
nitrobenzyl)-6-thioguanosine, were obtained in SDF format from the electronic LOPAC 
library, test group RK-001. Partial charges were added to each ligand atom using 
MMFF94s forcefield parameters and the structures were energy minimized to a gradient 
of 0.1 kcal/mol·Å. The energy-minimized ligands were docked into three structural 
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variations of 1AT: M* intermediate (Homology Model 126), mutant Z-1AT (PDB: 3T1P) 
and wild type M-1AT (PDB: 3CWM) using the docking function built into MOE. Binding 
sites were identified using the MOE Site Finder facility. Separate docking simulations of 
the 80 compounds were carried out for each receptor and at each potential binding site. 
Initial placement of ligand atoms was done with the Triangle Placement method (seeds 
in 3 atoms at time). The predicted free energy of binding for each initially docked ligand 
pose was calculated using the London dG(“Chemical Computing Group - Citing MOE,” 
2012) scoring method from within MOE. The top five scoring poses were further energy 
minimized using the MMFF94s force field, allowing ligand atoms and protein side chains 
within 6 Å of each docked ligand to be treated as flexible. A tethering weight of 10 
kcal/mol/Å2 was applied to partially restrain flexible atoms around their original location. 
A final docking score for each energy-minimized pose was calculated using the Affinity 
dG(“Chemical Computing Group - Citing MOE,” 2012) scoring method. 
A.3 Experimental results 
A.3.1 Principal characteristics of the Z-1AT polymerization inhibitor screening assay 
Previous studies have shown that a 6-mer peptide whose amino acid sequence contains 
the RCL sequence FLEAIG can specifically bind the Z-mutant at its opened s4A pocket, 
but not the wild type. (Mahadeva et al., 2002) The Z-1AT high-throughput microplate 
screening assay is based on this concept. Thus, we designed a similar peptide and added 
a biotin-polyethylene glycol (bPEG) tag at the Cterm of the reactive loop sequence as well 
as some hydrophilic amino acids to increase peptide solubility. The insertion of a PEG-
based spacer prevents possible steric hindrance between the peptide and the biotin 
molecule, resulting in better avidin binding and therefore, a more accurate measurement 
of the biological activity.   
To assess the ability of small molecules to inhibit the recruitment of the bPEG-peptide 
into Z-1AT, microtiter plate wells containing attached Z-1AT are subjected for 3 min to 
library compound before addition of bPEG-peptide. The amount of bPEG-peptides 
incorporated into the mutant protein is then determined by a europium-streptavidin 
treatment and time-resolved fluorescence measurements. The inhibition effect of a 
compound is calculated as a percentage with respect to a reaction control – i.e. Z-1AT 
that has only been exposed to the biotinylated peptide and not to a compound. Any 
compound showing an inhibitory effect of at least 50% is considered as a hit. Regarding 
its ability to bind Z-1AT, we found the bPEG-peptide association kinetics to be in favor 
of the mutant proteinase with an initial association rate of 0.22 ± 0.08 fmoles·h-1 vs. 0.042 
± 0.1 fmoles·h-1 for the wild type, Figure A.1A. We also found that an incubation period of 
16 hrs for the peptide with Z-1AT is an adequate screening end-point for the screening 
assay as this time period is associated with a high signal-to-noise ratio. In addition, the 
presence of 5% DMSO in the wells does not affect the bPEG-peptide binding kinetics,  
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Figure A.1.  Kinetic diagram of bPEG-peptide binding to 1AT. (A) Four micrograms per 
well of attached () Z-1AT or () M-1AT were incubated for various times in presence 
of 38.4 M bPEG-peptide. (B) Z-1AT was incubated in presence of 5% DMSO and 
bPEG-peptide for 16 h. Errors bars reflect the standard deviation of three replicates. 
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Figure A.1B.  Since compound libraries are generally stored in DMSO, this feature makes 
the assay well suited for a high-throughput screening assay. Finally, this screening assay 
exhibits very good reproducibility as reflected by the error bars shown in Figure A.2. It 
requires only small amount of protein and low concentrations of bPEG-peptide, which 
make it both economical and physiological.  
 
 
 
Figure A.2. Pattern of inhibition resulting from the screening of 80 unknown LOPAC 
compounds. A 96-well plate was coated with 4 g/well of Z-1AT and incubated for 16 h 
with 100 M of various compounds and 38.4 M of bPEG-peptide. The black arrow 
indicates the compound that corresponds to S-(4-nitrobenzyl)-6-thioguanosine and gives 
an inhibition effect of 67 ± 2 % and. The error bars are the standard deviation of three 
individual experiments. 
 
 
A.3.2 S-(4-nitrobenzyl)-6-thioguanosine identified as inhibitor of Z-1AT polymerization 
The test group RK-001 (80 compounds) of the small commercially available LOPAC 
library containing drug-like molecules was used to test the performance of the screening 
assay. Figure A.2 shows a typical screening result. As indicated in the figure, only one 
compound of the tested compound plate appears as a hit, exhibiting a 67 ± 2 % inhibition 
activity at 100 M. This compound is S-(4-nitrobenzyl)-6-thioguanosine. To confirm its 
ability to inactivate Z-1AT polymerization, dose-responses curves were carried out and 
an IC50 of 73 ± 0.12 µM calculated, Figure A.3A. The IC50 value obtained is in the 
micromolar range and matches well with the screening results.  
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To define a better pharmacophore, and therefore to identify any additional structural 
element required for inhibiting Z-1AT polymerization, we then compared our compound 
to the entire database that regroups all of the LOPAC molecules. Surprisingly, we found 
another compound that possesses a very similar structure, differing by a single amino 
group, but that did not show any inhibitory effect, neither during the original screening nor 
in the validation assay, Figures A.3A and A.3B. 
A.3.3 Validation of the action of S-(4-nitrobenzyl)-6-thioguanosine 
A polymerization reaction was set up in presence or absence of 100 µM of S-(4-
nitrobenzyl)-6-thioguanosine and the disappearance of the Z-1AT monomer monitored 
by RP-HPLC – a diminution in monomer concentration indicates that the protein has been 
recruited into polymers. We found that Z-1AT has its polymerization rate decreased 33 
times in presence of the compound and that its effect is long lasting, Figure A.4.  
An additional approach to validate the action of S-(4-nitrobenzyl)-6-thioguanosine was to 
carry out an in silico molecular modeling and simulation strategy with the intent to gain 
mechanistic insights into how this small molecule may interact with the protein structure 
and prevent polymerization. Therefore, virtual docking and homology modeling were used 
to explore hypothetical binding sites and their putative molecular interactions.  
A.3.4 Structural modeling of 1AT and the M* intermediate  
In order to investigate all of the potential binding sites of S-(4-nitrobenzyl)-6-
thioguanosine on 1AT, including the ones located in the s4A cavity at the RCL insertion 
site, we used two PDB crystal structures, 1QLP and 3T1P, which respectively correspond 
to the wild type M-1AT and polymerized Z-1AT states. However, as the s4A cavity 
does not exist in any crystal structure of 1AT, a theoretical model comparable to M* had 
to be created. The M* intermediate state is described to have the following three structural 
features: i) an expanded β-sheet A with a s4A cavity between s3A/s5A, ii) an RCL at the 
precipice of inserting between s3A/s5A, and iii) the Cterm loop inserted within β-sheet B 
and not participating in a domain swap with another protein. These important features of 
the M* model are represented in the homology model built from the two available crystal 
structures of 1AT, Figure A.5. 
To build the M* state homology model, a total of five protein fragments of the two crystal 
structures, 1QLP and 3T1P, were merged. Figure A.6 shows that fragment 1 consists of 
residues 1-105 (1QLP) which model the right side of β-sheet B, with respect to beta 
strands adjacent to the right side of the Cterm loop. Fragment 3 consists of residues 205-
291 which constitute the left side of β-sheet B, with respect to beta strands adjacent to 
the left side of the Cterm loop. Together these two fragments model the position of β-sheet 
B so that the RCL residues from fragment 5 (residues 345-394 from 1QLP) can be placed  
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Figure A.3. S-(4-nitrobenzyl)-6-thioguanosine inhibits bPEG-peptide binding to Z-1AT. 
(A) Dose-response curves were assayed for various concentrations of  () S-(4-
nitrobenzyl)-6-thioguanosine and () its homologue S-(4-nitrobenzyl)-6-thioinosine. (B) 
Chemical structures of (left) S-(4-nitrobenzyl)-6-thioguanosine and (right) S-(4-
nitrobenzyl)-6-thioinosine. The errors bars are the standard deviation of an experiment 
conducted in triplicate. 
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Figure A.4.  Effect of S-(4-nitrobenzyl)-6-thioguanosine on Z-1AT polymerization. The 
protein was incubated with () or without () 100 M of S-(4-nitrobenzyl)-6-thioguanosine 
for various time at 37 ºC. The error bars are the standard deviation of three separate 
experiments. 
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Figure A.5. The three models of 1AT protein. (Top left) Structure of wild type (PDB: 
1QLP) with the RCL not inserted and β-sheet A not expanded. (Top right) Structure of Z-
mutant (PDB: 3T1P) with the RCL inserted and β-sheet A expanded. (Bottom middle) 
Intermediate M* model with an expanded β-sheet A (retained from structure 3T1P), RCL 
not inserted into the RCL cavity (retained from structure 1QLP), and Cterm loop inserted 
into β-sheet B (retained from structure 1QLP). (Purple) Strands 3 and 5 from β-sheet A. 
(Dark blue) Cterm loop within β-sheet B. (Light blue) RCL. (Orange) Residues of the RCL 
corresponding to the analogous 6-mer peptide. (Black arrows) s4A cavity. 
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on the outside of the s4A pocket along with the Cterm loop buried within β-sheet B. The 
position of strands s1A, s2A, and s3A in β-sheet A are modeled from fragment 2 (residues 
s4A between s3A/s5A, which would otherwise be the site of RCL insertion. This opened 
conformation of 1AT represents one of the possible structures of the unstable M* 
intermediate state for which experimental methods such as crystallography cannot 
reproduce. 
A.3.5 Analysis of 1AT structures and their potential binding sites  
All of the 80 in vitro screened compounds, including S-(4-nitrobenzyl)-6-thioguanosine, 
were docked into every potential binding site to assess if the computational result is 
comparable to the in vitro screening. A binding site able to dock S-(4-nitrobenzyl)-6-
thioguanosine with a lower binding energy than the 79 other compounds would be a 
promising site for further experimental investigations.  
Six putative binding sites were predicted among the three available protein models: M-
1AT, Z-1AT and intermediate M*, Figure A.7. SITE1 and SITE5 were both exclusively 
available in the M* model and are located in the RCL insertion site. SITE2 was found in 
all three models. It is also where the compound citrate, previously reported to lower 
polymerization rates (Pearce et al., 2008) has been observed to bind in the 3CWM wild 
type structure. Also found in all three models are: SITE3, a large cavity adjacent to SITE2; 
SITE4 situated near the Cterm edge of β-sheet A; and SITE6 located near the Nterm edge 
of β-sheet A. SITE6 is partially occluded in the M* model due to the expansion of β-sheet 
A.  
A.3.6 S-(4-nitrobenzyl)-6-thioguanosine binds at the RCL insertion site or on the edge of 
β-sheet A  
Docking of all 80 small molecules was performed with each model and at each putative 
binding site in order to compare how strongly S-(4-nitrobenzyl)-6-thioguanosine binds 
relative to the 79 other experimentally tested compounds. These results are summarized 
in Table A.1 and present two possible binding sites where S-(4-nitrobenzyl)-6-
thioguanosine can favorably bind to block RCL insertion. Results from docking at SITE5, 
the RCL insertion site, show S-(4-nitrobenzyl)-6-thioguanosine ranking first among the 
other 79 ligands which may suggest a mechanism where the RCL is directly blocked at 
the RCL insertion site. Interestingly, S-(4-nitrobenzyl)-6-thioguanosine is also found to 
rank first in the wild type model when docked at SITE6. Figure A.8 compares the location 
of SITE6 in both the M- and Z-1AT structures which illustrates how binding of S-(4-
nitrobenzyl)-6-thioguanosine at SITE6 may prevent the expansion of β-sheet A and 
possibly prevent RCL insertion. Lesser sites of interest, which only rank S-(4-nitrobenzyl)-
6-thioguanosine in the top 10% of ligands, are SITES 1 and 2. SITE1 is also part of the 
RCL insertion site. SITE2 has been previously reported as the binding site for citrate 
61 
 
 
 
Figure A.6. The fragments of structures 1QLP (green) and 3T1P (red) used to homology 
model the M* intermediate state of 1AT. β-sheet A is the red beta sheet across the top 
half of the model and β-sheet B is the green beta sheet across the bottom of the model. 
Residue numbers at the start and end of each fragment transition are labeled with an 
arrow in the Nterm to Cterm direction. Shades of green and red distinguish discontinuous 
fragments from the same initial crystal structure (light/dark green for 1QLP fragments and 
light/dark red for 3T1P fragments). 
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Figure A.7. Binding Sites for S-(4-nitrobenzyl)-6-thioguanosine. Two protein ribbon 
models are shown for each structure: (A) 3CWM, (B) 3T1P and (C) M* Model. The left 
model and right representations in each panel are rotated 90° with respect to one another. 
The best binding poses for S-(4-nitrobenzyl)-6-thioguanosine at each available binding 
site are shown with space filling atoms with the carbon atoms colored green. (Purple) 
Strands 3 and 5 from β-sheet A. (Dark blue) Cterm loop within β-sheet B. (Light blue) RCL. 
(Orange) Residues of the RCL corresponding to the analogous 6-mer peptide.  
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Figure A.8. Two crystal structures for 1AT are superimposed and represented in ribbon 
diagram. S-(4-nitrobenzyl)-6-thioguanosine is represented with space filling atoms and 
positioned at SITE6 for the M-1AT structure (1QLP). (Dark blue) Z-1AT structure 
(3T1P) with an expanded β-sheet A. (Dark grey) Wild type structure 3CWM with β-sheet 
A not expanded into SITE6. (Light blue) expanded β-strand s2A in structure 3T1P, which 
occupies SITE6. (Light grey) β-strand s2A in structure 1QLP adjacent to SITE6.  
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which can also prevent polymerization and whose mechanism of action has yet to be 
determined (Pearce et al., 2008). 
A.3.7 Residue interactions with S-(4-nitrobenzyl)-6-thioguanosine  
Nearby residues that interact with S-(4-nitrobenzyl)-6-thioguanosine at the top ranking 
sites (SITE1, SITE2, SITE5) from the M* intermediate model and the single site (SITE6) 
from the wild type model are described in Table A.2. This information provides the basis 
for guiding further validations of these binding sites using techniques such as 
mutagenesis and molecular dynamics. Supplemental Figures S1-S4 contain additional 
details about the type of interactions formed between individual atoms of S-(4-
nitrobenzyl)-6-thioguanosine and the nearby residues listed in Table A.2.  
A.4 Discussion 
Currently, the only available and effective treatment to correct for the loss of 1AT 
function in 1ATD associated with liver disease is orthotropic liver transplantation. For 
lung disease, augmentation therapy is the only specific regiment that is thought to slow 
down disease progression, although this still requires formal proof through well-controlled 
clinical trials.(Gøtzsche & Johansen, 2010) As these treatments are expensive, labor 
intensive and associated with side effects, the need for novel treatments are indeed in 
high-demand. With Z-1AT polymerization being responsible for the development of the 
disease, blocking its aggregation by small molecules (Mallya et al., 2007; Pearce et al., 
2008) appears to be a promising strategy to cure Z-1ATD.  
Here we report an integrated in vitro and in silico approach which allows discovering and 
characterizing potent small molecules that disrupt the pathological polymerization of Z-
1AT. The in vitro microplate assay which enables the identification of small molecules 
able to block the insertion of a modified 6-mer peptide into the s4A cavity, provides 
quantitative data with reproducibility, sensitivity and rapid throughput. Our results validate 
the utility of the in vitro screening assay and identify S-(4-nitrobenzyl)-6-thioguanosine as 
inhibitor of Z-1AT polymerization. With a molecular weight of 434.43 Da, 4 H-bond 
donors, 11 H-bond acceptors and a low lipophilicity coefficient (XLogP3 =1.1), this 
compound presents a strong drug-like profile according to the Lipinski rule of 
five.(Leeson, 2012) From IC50 determination and structure-activity relationship studies, 
we also found one of its structural homologues which differs by a single amino group and 
does not prevent aggregation. This suggests that an interaction with the amino group may 
be important to counteract the insertion of the modified 6-mer peptide.  
The microplate assay has been designed to identify any inhibitor that can impede the 
insertion of the RCL into the s4A cavity, but it does not exclude the discovery of small 
molecules that can bind outside of the s4A cavity, causing a conformational 
rearrangement that still precludes RCL insertion. Molecular docking experiments were 
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carried out to investigate binding of S-(4-nitrobenzyl)-6-thioguanosine at several potential 
binding locations, in addition to the s4A cavity. A chimera homology model of the 
intermediate state, M* model, was built in order to allow investigation of the s4A cavity. 
Until now, previous studies have only used molecular docking to investigate the binding 
of small molecules into experimentally resolved structures and only at sites other than the 
s4A cavity. 
The development for the first time of an atomistic M* model reveals a mechanism through 
which S-(4-nitrobenzyl)-6-thioguanosine may inhibit Z-1AT polymerization by either 
competing with the RCL at the s4A insertion site (SITE5) or by  blocking the s4A cavity 
from forming by binding at a nearby location (SITE6). To definitely discriminate between 
these two binding sites, additional structural studies will need to be carried out beyond 
the scope of the present work which will include selected mutagenesis and molecular 
dynamics (MD). MD simulations, which provide an ensemble of various conformations of 
M*, will account for the protein flexibility38,39 and will aid in refining the docking results. 
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Table A.1. Docking results from M-1AT, Z-1AT, and M* model with S-(4-nitrobenzyl)-
6-thioguanosine and the 79 other small molecules. 
 
Structure SITEα 
Lowest Energy β 
 (kcal/mol) 
B9 Energy γ 
(kcal/mol) 
B9 Rankδ 
M-1AT (3CWM) 
SITE1 n/a Θ n/a n/a 
SITE2 -7.0 -5.6 19th 
SITE3 -6.2 -5.3 8th 
SITE4 -6.4 -3.4 25th 
SITE5 n/a n/a n/a 
SITE6 -7.6 -7.6 1st 
Z-1AT (3T1P) 
SITE1 n/a n/a n/a 
SITE2 -6.5 -3.9 34th 
SITE3 -9.0 -5.8 13th 
SITE4 -4.6 -3.6 19th 
SITE5 n/a n/a n/a 
n/a SITE6 n/a n/a 
M* Model 
SITE1 -10.7 -7.9 7th 
5th SITE2 -10.7 -8.8 
SITE3 -5.1 -4.6 9th 
SITE4 n/a n/a n/a 
SITE 5 -8.4 -8.4 1st 
SITE6 -6.2 -4.22 12th 
α Site number where S-(4-nitrobenzyl)-6-thioguanosine (B9) was docked. β Lowest observed binding energy 
(kcal/mol) for any of the 80 docked compounds. γ Predicted binding energy (kcal/mol) for B9. δ Rank of B9 
relative to the binding energies for all 80 docked compounds. Θ Site numbers that are not found in a given 
model are noted by a not applicable symbol (n/a). 
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Table A.2. Residues interacting with S-(4-nitrobenzyl)-6-thioguanosine in top scoring 
binding sites. 
M* Model 
SITE 1 
S34, I35, A37, F38, L41, L149, T157, F159, A160, L161, V162, 
N163, Y164, L276, F289, L304, K305, L306, K308, A309, V310, 
H311 
SITE 2 
W171, E172, R173, P174, F175, R200, M203, F204, N205, 
L218, M219, K220, Y221, F229, E256, D257, R258, L263, L265, 
I317, D318, F329, E331 
SITE 5 
F28, K145, I146, I165, F166, F167, K168, V314, L315, C316, I 
317, D318, E319, K320, G321, T322, E323, A324, M351, F361 
M-1AT 
(3CWM) 
SITE 6 
S56, T59, A60, M63, L100, N104, Q105, L112, T113, T114, 
G115, N116, G1117, Y138, H139, S140, E141, Y160, G164, 
N186, Y187, I188 
Listed are the interacting residues for binding sites where S-(4-nitrobenzyl)-6-
thioguanosine ranks in the top 10% of compounds and less than -7kcal/mol. 
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Appendix B 
Alpha-1 Antitrypsin Mammalian Cell Work 
 
Alpha-1 antitrypsin deficiency (1ATD) is a disorder associated with chronic liver and/or 
lung disease [116]. In this condition, the lack of circulating alpha-1 antitrypsin in the blood 
stream leads to emphysema, and the abnormal accumulation of alpha-1 antitrypsin in the 
liver leads to hepatocellular diseases such as cirrhosis [117, 118]. While there are over 
100 variants associated with 1AT, the Z variant of (Zα1AT) is the most common and 
severe form of Alpha1 Antitrypsin deficiency (1ATD) [119]. Zα1AT pathogenesis is 
amplified based on the ability of the disease-protein to form polymers in hepatocytes, 
inhibiting its secretion into the blood [120]. At present, there is no cure for 1ATD. 
Although many new therapies are in the pipeline to help cure 1ATD, the only available 
therapy to prevent lung disease progression is limited to augmentation therapy and organ 
transplant [121, 122]. It is hypothesized that breaking these hepatocyte polymers will 
reduce polymer accumulation in the liver and increase alpha-1 antitrypsin in the blood, 
thereby reducing the risk of disease [123, 124].  
To discover small compounds and polymerization breakers, we utilized an in vitro and in 
silico approach to identify potential drug candidates, as identified in appendices A. Based 
on our results, we identified one excellent candidate B9 (S-(4-nitrobenzyl)-6-
thioguanosine), along with 10 other potential candidates from in silico experiments that 
needed to be tested further [125]. To test these potential drug candidates and further test 
B9, we created a controlled expression system in liver hepatocellular carcinoma (HepG2) 
cells, to monitor the polymer reduction. 
In this regard, Expression Constructs offer an in vitro controlled system that allows 
experimentalists to examine the genes and proteins of interest. For this study, we will be 
using the T-RExCell Expression system from Life Technologies. This expression system 
contains two plasmids, namely the inducible expression plasmid pcDNA4/TO and the 
repressor plasmid pcDNA6/TR that represses the transcription of pcDNA4/TO. Notably, 
in the absence of tetracycline, the 6/TR repressor binds to 4/TO and transcription is 
arrested. On the other hand, in the presence of tetracycline, tetracycline binds to the 
repressor and activates transcription; see Figure B.1 [126]. In this context, creating a 
controlled system will allow us to control and monitor the production of polymers. Ideally, 
a stable mammalian construct is the best option for obtaining these desired results, but 
transient systems are also capable of producing comparable results. To create a 
mammalian expression system, both Zα1AT and Mα1AT will need to be ligated to the 
pcDNA4/TO expression vector designed for the T-REx system [127, 128]. Once 
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confirmed, mammalian Hep G2 cells will be transfected or co-transfected with 
pcDNA4/TO, Zα1AT/ Mα1AT and/or pcDNATM6/TR vector to create a stable expression 
system for testing compounds that prevent polymerization; see Figure B.2.  
The mammalian system that we created for this study functions in two parts. The first part 
of the system has been created to monitor polymer production intracellularly. This 
construct consists of Zα1AT/Mα1AT protein with a 6xhis-tag and a no signal peptide, which 
will be used to monitor the breaking of polymers intracellularly. The lack of the signal 
peptide will allow us to monitor polymer production and reduction in the cytoplasm of this 
mammalian cell system. The second construct consists of Zα1AT/Mα1AT protein with a 
6xhis-tag and a signal peptide to monitor the functionality of the protein after treatment 
with the potential therapeutics. Upon the addition of the potential drug candidate, the 
polymerization should reduce significantly and be secreted into the media, where we can 
then measure the functionality of the protein. For the remainder of this discussion, these 
constructs will be called intracellular and full-length constructs; M is for wildtype and Z is 
for the mutant. 
B.1 Method and results 
B.1.1. Construction of pcDNA4/TO, Mα1AT (intracellular and full length) and 
pcDNA4/TO, Zα1AT (intracellular and full length) 
To begin with, both Mα1AT and Zα1AT DNA intracellular fragments were digested from 
the pPic3.5K vector with the restriction enzymes BamHI and EcoRI. Then,  according to 
the manufacturer’s instructions, the Mα1AT and Zα1AT fragments (1278bp) were 
subcloned into pcDNA4/TO (5078bp) using T4 DNA ligase. Following ligation, 
transformation was carried out in MAX Efficiency DH5αTM E. coli cells and selected for 
100 µg/mL Ampicillin. The resulting plasmid was verified by restriction digests (Figure 
B.3). Moreover, both Mα1AT and Zα1AT DNA full length fragments were synthesized by 
GenScript and verified, Figure B.4 and B.5. After verification of Mα1AT and Zα1AT in both 
intracellular and full length, these constructs were ready to be used to transfect 
mammalian cells.  
B 1.2. HepG2 transfection optimization 
Importantly, establishing a transfection protocol for each mammalian cell line is critical for 
transient and stable transfection studies. To establish an efficient protocol, various 
transfection reagents were used and tested against a GFP expression plasmid; see Table 
1. For GFP expression, 1-3 µg of DNA per well in 6 well plates were used. , As per the 
manufacturer’s directions, the ratios for lipofectamine reagents were 1:3 to 1:5 DNA (µg). 
Based on our transfection results, we could identify 4 candidate transfection reagents to 
be used with our constructs. Next, we next analyzed the top 4 transfection reagents 
(Lipofectamine LTX reagent with plus reagent, Lipofectamine 3000 transfection reagent, 
metafectene Pro, and TransIT-LT1) with our constructs pcDNA4/TO Mα1AT and  
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Figure B.1: Figure from Invitrogen, life technologies. Components of the T-REx system, 
pcDNA6/TR is generating the repressor for pcDNA4/TO, which is the inducible expression 
plasmid (T-Rex TM system, 2011).  
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Figure B.2: Figure taken from Invitrogen, life technologies: pcDNA4/TO can be 
transfected transiently to produce constitutive expression of Zα1AT/Mα1AT or it can be 
co-transfected with pcDNA6/TR to demonstrate that the system may be inducible (T-Rex 
TM system, 2011). 
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Figure B.3: Verification of (A) pcDNA4/TO Mα1AT, (B) pcDNA4/TO Zα1AT DNA 
intracellular constructs. 
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Figure B.4: pcDNA4/TO, Mα1AT Vector used for expression in HepG2 cells. 
78 
 
 
Figure B.5: pcDNA4/TO, Zα1AT Vector used for expression in HepG2 cells. 
 
 
 
 
 
 
 
79 
 
Table B.1: Transfection reagent optimization with various transfection reagents. 
Lipofectamine 3000 transfection reagent responded the best for Mα1AT and Zα1AT. 
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Figure B.6: Transient transfection 48 hours after transfection with lipofectamine 3000 
transfection reagent in HepG2 cells. (A) pcDNA4/TO Mα1AT; (B) pcDNA4/TO Zα1AT. 
 
pcDNA4/TO Zα1AT. We then transfected HepG2 cells with Mα1AT and Zα1AT, allowed 
them to express for 48 hours and later imaged them using the Leitz DMRB Fluorescence 
Microscope (Complete protocol below).  It was observed that the Lipofectamine 3000 
transfection reagent responded well for both Mα1AT and Zα1AT with a transfection 
efficiency between ~10 and 20%; see Figure B.6 for details. In addition to testing 
transfection efficiency, we also wanted to check cellular toxicity with each of the reagents. 
Trypan Blue (0.4%) was used to count viable cells in each culture. Not only did 
lipofectamine 3000 have the best transfection with our constructs, but it also showed the 
minimal cellular toxicity in most cases; see Table 1 for more information.  
B.1.3. Transient transfection test with Mα1AT and Zα1AT 
Significantly, transient transfections of HepG2 and COS-7 cells have been used to study 
a variety of serpins and their polymerization mechanisms [129, 130]. Hence, 6 well plates 
(with cover slips for imaging) were coated with poly-L-lysine (125mg per well) and 
incubated for an hour; these plates were then allowed to dry overnight in a sterile cabinet. 
Because HepG2 cells tend to clump, adding poly-L-Lysine aids in the cells forming a 
monolayer; therefore 200,000 HepG2 cells were plated in a 2 mL culture containing 
EMEM + 10% FBS. After the cells grew to a confluency of about 60%, the pcDNA4/TO 
plasmids encoding wild type (Mα1AT) and mutant (Zα1AT) were transfected into HepG2 
cells with Lipofectamine 3000 (following transfection ratios from above). Afterward, the 
transfection serum medium was removed and replaced with EMEM and no FBS, and then 
incubated at 37°C incubator with 5% CO2 for 3-5 hours. After incubation, the serum 
medium was added (EMEM + 10% FBS) back to the wells and assayed for expression 
between 24-72 hours (protocol below). 
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B.1.4. Fixing and staining cells for expression 
At each time point (24h, 48h, and 72h), cells were fixed using a BD Cytofix Fixation Buffer. 
First, the cells were washed with 1X PBS. Then, 500ul of BD Cytofix Fixation Buffer was 
added and the cells were incubated at room temperature for 15-30 minutes; alternatively, 
a fixing buffer with (0.2%) gluteraldehyde and (4%) formaldehyde can be used. Finally, 
the cells were washed two more times with 1X PBS and placed back in 1X PBS, until they 
were ready to be stained with antibodies. Although fixed cells can be stored at 4ºC for up 
to 3 weeks, it is always recommended to do the staining as soon as possible.  
B.1.5. Immunofluorescence in HepG2 cells  
To detect our constructs in both wild type (Mα1AT) and mutant (Zα1AT), we used 2 
different antibody conjugates. The first antibody was used to detect alpha-1 antitrypsin in 
both wild type (Mα1AT) and mutant (Zα1AT). Here, we used a Labelled StrepAvidin Biotin 
(LSAB) method; we also used the goat polyclonal to alpha-1-antitrypsin (HRP) (ab7635) 
and conjugated that antibody to the secondary antibody (anti goat streptavidin), which in 
turn was conjugated to a tertiary antibody anti-streptavidin; this combination was 
conjugated to an Alexa Fluor 594 dye (Red fluorescence) where we could indirectly 
monitor fluorescence. The second antibody was used to detect the His-tag within the 
constructs. The his-tag antibody was a mouse monoclonal His.HB to 6X His tag® 
(ab18184), and it was conjugated to a secondary His-tag antibody, namely the anti-mouse 
Alexa Flour 488 (Green fluorescence). All the antibodies used in these experiments were 
at a working concentration of 1/1000U.  
Then, HelpG2 cells were permeabilized with 1X PBS and 0.2% Triton X-100 for 5 minutes, 
and then washed in 1X PBS for 5 minutes 3x. Nonspecific binding sites were blocked 
using a blocking buffer for 30 minutes; the Blocking Buffer consisted of PBST (1X PBS + 
0.1% Tween 20) and 1% BSA. Following incubation, the primary antibody was added and 
incubated for 1 hour, and then washed with 1X PBS for 5 minutes 3x. The same procedure 
was repeated for secondary and tertiary antibodies. Then, there was a final wash with 1X 
PBS for 5 minutes. Finally, a 1X PBS and Hoechst stain (Blue fluorescence, nucleus 
stain) solution was applied and incubated for 5 minutes; next, the cells were washed again 
in 1X PBS for 5 minutes 2x. Subsequently, the cells were visualized using the Leitz DMRB 
Fluorescence Microscope at magnifications between 10-40X. 
Afterwards, each of the two constructs, intracellular and full length, were analyzed with 
both antibody conjugates. The intracellular construct pcDNA4/TO Mα1AT and Zα1AT was 
analyzed over a period of 24-72 hours. At each time point, the above protocol was applied 
with the alpha-1-antitrypsin antibodies. These data showed that after 24 hours of 
incubation, we see minimal expression of either wild type or mutant. Between 48 and 72, 
we get the best expression from both constructs, with the mutant expressing the best at 
72 hours, see Figure B.7 for additional information. Additionally, we analyzed this 
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construct using the His-tag antibodies and found the same results; please note that data 
corresponding to this analysis is not shown. Using the His-tag antibody conjugates, we 
analyzed the full-length construct for both pcDNA4/TO Mα1AT and Zα1AT at 48 hours; 
see Figure B.8 for details. These data show that the full-length protein is expressed in the 
sample. We also measured the alpha 1 antitrypsin antibody and found the same results; 
the resultant data is not shown.  
B.2 Conclusion 
Given the seriousness of 1ATD and its potentially dire consequences, evaluating the 
efficacy of treatments to mitigate this disease is vital. Collectively, these aforementioned 
data from our study have shown that we have an inducible transient system that could be 
utilized for drug monitoring and drug screening assays. Our intracellular construct, 
comprising both wildtype and mutant, is sufficient for monitoring the reduction of polymers 
in the cytoplasm after the treatment with a drug. Our full-length construct, comprising both 
wild type and mutant, is sufficient for monitoring intracellular expression and extracellular 
expression after the treatment with a drug. Additionally, this construct could be used to 
monitor the secretion of Zα1AT and may also be used to test the functionality of the Zα1AT 
mutants. The comprehensive data obtained from our system can be used to choose the 
most efficacious treatment to cure or control 1ATD and its attendant risks.      
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Figure B.7: This is the intracellular construct for both wild type (Mα1AT) and mutant 
(Zα1AT) expressed in HepG2 cells.  
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Figure B.8: This is the full-length construct for Mα1AT, Zα1AT, and control expressing at 
48 hours’ post transfection: (A) is control HepG2 along with minimal background; (B) 
Mα1AT; (C) Zα1AT.  
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